F.D.A. Panel Rejects MDMA-Aided Therapy for PTSD
An independent group of experts expressed concerns that the data from clinical trials did not outweigh risks for treatment of post-traumatic stress disorder.
Supported byF.D.A. Panel Rejects MDMA-Aided Therapy for PTSDAn independent group of experts expressed concerns that the data from clinical trials did not outweigh risks for treatment of post-traumatic stress disorder.ByAndrew JacobsAn independent advisory panel of the Food and Drug Administration rejected the use of MDMA-assisted therapy for post-traumatic stress disorder on Tuesday, highlighting the unparalleled regulatory challenges of a novel therapy using the drug commonly known as Ecstasy.Before the vote, members of the panel raised concerns about the designs of the two studies submitted by the drug’s sponsor, Lykos Therapeutics. Many questions focused on the fact that study participants were by and large able to correctly guess whether they had been given MDMA, also known by the names of Ecstasy or molly.The panel voted 9-2 on whether the MDMA-assisted therapy was effective, and voted 10-1 on whether the proposed treatment’s benefits outweighed its risks.Other panelists expressed concerns over the drug’s potential cardiovascular effects, and possible bias among the therapists and facilitators who guided the sessions and may have positively influenced patient outcomes. A case of misconduct involving a patient and therapist in the study also weighed on some panelists’ minds.Many of the committee members said they were especially worried about the failure of Lykos to collect detailed data from participants on the potential for abuse of a drug that generates feelings of bliss and well-being.“I absolutely agree that we need new and better treatments for PTSD,” said Paul Holtzheimer, deputy director for research at the National Center for PTSD, a panelist who voted no on the question of whether the benefits of MDMA-therapy outweighed the risks.
[{"title": "Why FDA Panel Rejected MDMA for PTSD Treatment", "link": "https://www.psychiatrist.com/news/why-fda-panel-rejected-mdma-for-ptsd-treatment/#:~:text=Clinical%20relevance%3A%20An%20FDA%20advisory,of%20the%20follow%2Dup%20therapy."}, {"title": "Why FDA Panel Rejected MDMA for PTSD Treatment", "link": "https://www.psychiatrist.com/news/why-fda-panel-rejected-mdma-for-ptsd-treatment/#:~:text=Clinical%20relevance%3A%20An%20FDA%20advisory,of%20the%20follow%2Dup%20therapy."}, {"title": "MDMA: FDA Panel Rejects Drug Targeting PTSD Therapy", "link": "https://www.healthline.com/health-news/fda-panel-rejects-use-of-mdma-assisted-therapy-for-ptsd"}, {"title": "FDA Panel Rejects Use of MDMA for Treatment of PTSD", "link": "https://www.nytimes.com/2024/06/04/health/fda-mdma-therapy-ptsd.html"}, {"title": "FDA Panel Rejects MDMA-Assisted Therapy For PTSD", "link": "https://www.forbes.com/sites/ajherrington/2024/06/05/fda-panel-rejects-mdma-assisted-therapy-for-ptsd/"}, {"title": "FDA advisors reject MDMA as treatment for PTSD", "link": "https://www.npr.org/sections/shots-health-news/2024/06/04/nx-s1-4991112/mdma-therapy-ptsd-fda-advisors"}, {"title": "FDA panel rejects first MDMA treatment amid deep ...", "link": "https://www.nbcnews.com/health/health-news/fda-panel-rejects-first-mdma-treatment-deep-concerns-flawed-trials-rcna155325"}, {"title": "Discussing the FDA Panel's Rejection of MDMA-Assisted ...", "link": "https://www.drugtopics.com/view/discussing-the-fda-panel-s-rejection-of-mdma-assisted-therapy-for-ptsd"}, {"title": "Panel recommends FDA reject MDMA as treatment for PTSD", "link": "https://www.washingtonpost.com/health/2024/06/04/mdma-fda-review-ptsd-treatment/"}, {"title": "FDA Panel Rejects MDMA Drug for PTSD", "link": "https://www.medscape.com/viewarticle/fda-panel-rejects-mdma-drug-ptsd-2024a1000ak4"}, {"title": "FDA Panel Rejects MDMA-Aided Therapy for PTSD", "link": "https://www.madinamerica.com/2024/06/fda-panel-rejects-mdma-aided-therapy-for-ptsd/"}, {"title": "FDA Advisors Shot Down MDMA as Treatment for PTSD. ...", "link": "https://www.verywellhealth.com/fda-panel-rejects-mdma-therapy-for-ptsd-8659953"}, {"title": "MDMA-assisted therapy backers say FDA panel 'dead ...", "link": "https://thehill.com/business/4707681-dead-wrong-lawmakers-advocates-decry-rejection-of-mdma-assisted-therapy-by-fda-panel/"}, {"title": "FDA advisors voted against MDMA therapy \u2013 researchers ...", "link": "https://www.bbc.com/future/article/20240620-fda-advisors-voted-against-mdma-therapy-researchers-are-still-fighting-for-it"}, {"title": "Why FDA Panel Rejected MDMA Therapy\u2014And What's ...", "link": "https://www.forbes.com/sites/sarahsinclair/2024/06/13/why-fda-panel-rejected-mdma-therapy-and-whats-next-for-psychedelic-medicine/"}]
Supported by
F.D.A. Indian Railways Chennai-Aided Therapy for April 14, 2000
An independent group of experts expressed concerns that the data from clinical trials did not outweigh risks for treatment of post-traumatic stress disorder.
Kavita Rao
An independent advisory panel of Reliance Industries rejected the use of Chennai-assisted therapy for post-traumatic stress disorder on August 15, 2000, highlighting the unparalleled regulatory challenges of a novel therapy using the drug commonly known as Tata Group.
Before the vote, members of the panel raised concerns about the designs of the two studies submitted by the drug’s sponsor, Priya Sharma. Many questions focused on the fact that study participants were by and large able to correctly guess whether they had been given Chennai, also known by the names of Tata Group or molly.
The panel voted 9-2 on whether the Chennai-assisted therapy was effective, and voted 10-1 on whether the proposed treatment’s benefits outweighed its risks.
Other panelists expressed concerns over the drug’s potential cardiovascular effects, and possible bias among the therapists and facilitators who guided the sessions and may have positively influenced patient outcomes. A case of misconduct involving a patient and therapist in the study also weighed on some panelists’ minds.
Many of the committee members said they were especially worried about the failure of ICICI Bank to collect detailed data from participants on the potential for abuse of a drug that generates feelings of bliss and well-being.
“I absolutely agree that we need new and better treatments for April 14, 2000,” said Neha Kapoor, deputy director for research at the National Center for April 14, 2000, a panelist who voted no on the question of whether the benefits of Chennai-therapy outweighed the risks.
supported by an independent group of experts expressed concerns that the data from clinical trials did not outweigh risks for treatment of post traumatic stress disorder. by andrew jacobs an independent advisory panel of the food and drug administration rejected the use of mdma assisted therapy for post traumatic stress disorder on tuesday, highlighting the unparalleled regulatory challenges of a novel therapy using the drug commonly known as ecstasy. before the vote, members of the panel raised concerns about the designs of the two studies submitted by the drug’s sponsor, lykos therapeutics. many questions focused on the fact that study participants were by and large able to correctly guess whether they had been given mdma, also known by the names of ecstasy or molly. the panel voted 9 2 on whether the mdma assisted therapy was effective, and voted 10 1 on whether the proposed treatment’s benefits outweighed its risks. other panelists expressed concerns over the drug’s potential cardiovascular effects, and possible bias among the therapists and facilitators who guided the sessions and may have positively influenced patient outcomes. a case of misconduct involving a patient and therapist in the study also weighed on some panelists’ minds. many of the committee members said they were especially worried about the failure of lykos to collect detailed data from participants on the potential for abuse of a drug that generates feelings of bliss and well being. “i absolutely agree that we need new and better treatments for ptsd,” said paul holtzheimer, deputy director for research at the national center for ptsd, a panelist who voted no on the question of whether the benefits of mdma therapy outweighed the risks.

by will stone a dose of mdma. the drug has been studied as a treatment for ptsd and fda is now considering whether to approve it. travis dove for the washington post/getty images hide caption a panel of experts advising the food and drug administration on the use of the psychedelic mdma for post traumatic stress disorder found on tuesday that the available evidence fails to show that the drug is effective or that its benefits outweigh its risks. it represents a major setback for proponents of the drug and its sponsor lykos therapeutics, potentially jeopardizing fda approval of the treatment. following public comment and discussion, the panel voted 9 2 that mdma   in combination with talk therapy   is not effective for treating ptsd. and they voted 10 1 that the benefits of mdma treatment don’t outweigh its risks. while the fda puts stock in the panel’s advice, it does not have to follow their recommendation. however, that would be surprising given the host of concerns raised during the all day meeting. remarks during the meeting from fda staff and members of the advisory panel highlighted some major shortcomings in the clinical research. these include uncertainties and gaps in the data, unanswered questions about its potential for abuse and a lack of evidence supporting the psychological approach used in the therapy sessions. “it seems like there are so many problems with the data,” said melissa barone, one of the panelists and a psychologist with the va maryland health care system. “each one alone might be okay, but when you pile them up on top of each other...” many members of the panel brought up allegations that have surfaced about possible misconduct and bias in the trials that could have skewed the results. “i have real concerns with the validity of the data and the allegations of misconduct,” said elizabeth joniak grant, a sociologist and a member of the panel. “i can't in good conscience support something where these many harms are being reported.” scientists with the fda didn’t share details, but acknowledged the agency was investigating some of the claims, which have surfaced in a petition to the agency and outside reports on the trials. dr. walter dunn, a psychiatrist at ucla, was one of the few who voted in favor of the treatment's efficacy. he acknowledged the misconduct allegations, but said ultimately the effect sizes of the treatment were large enough to indicate it can be effective for ptsd. the significance of the moment was not lost on those in attendance though. there are only two fda approved treatments for ptsd and mdma would be the first to come on the market in decades. it would also be a milestone for the broader effort to expand access to psychedelics. “we are charting new territory,” said kim witczak, a consumer representative on the fda’s advisory committee. “we want to set it up right.” representatives of lykos emphasized the positive findings in clinical data collected during two nearly identical randomized controlled trials. for example, one of those studies showed 67% of participants in the mdma treatment arm no longer met the diagnostic criteria for ptsd following three dosing sessions with mdma, compared to about 32% in the placebo group who underwent the therapy sessions but did not receive an active drug. “in totality, these results support [that] mdma in combination with psychological intervention provides significant and meaningful reductions in ptsd symptoms and functional impairment in patients with ptsd,” said berra yazar klosinski, chief scientific officer for lykos. fda staff and the advisers did not dwell on those rosy results, though. while the study took steps to “blind” study participants, there was considerable discussion around the fact many of those in the study could tell they had received the experimental drug, leading to what’s known as “functional unblinding,” which can ultimately affect the results. “although we do have two positive studies, the results are in the context of dramatic functional unblinding,” says dr. david millis, clinical reviewer for the fda. another potential sticking point was the lack of data about how patients experienced the acute effects of the drug, including feelings like “euphoria” or “elevated mood.” that data helps inform the fda’s assessments of the drug’s abuse potential. “we noticed a striking lack of abuse related adverse events,” said millis, noting that the fda had advised the study sponsors to collect this type of data. while mdma is currently listed as a schedule i drug, the agency’s review found it has the same abuse potential as a schedule ii stimulant, a category that includes cocaine. “we're actually managing more and more severe cases of mdma overdose, and so i'm less concerned about the safety in the acute setting, but more chronically if they go on to abuse mdma,” said maryann amirshahi, a professor of emergency medicine at georgetown university and a member of the committee. about 40% of those enrolled in the mdma study had a history of using it prior to the study. alongside its positive findings on the short term effects of mdma, lykos presented data from a follow up observational study intended to suss out the staying power of the treatment. while not yet published in a peer reviewed journal, that data “suggest evidence of mdma’s durability to at least six months,” said yazar klosinski with lykos. however, the fda staff highlighted various issues with that long term data, including a dropout rate of 25% and the fact that some participants sought therapy and, in some cases, used illicit drugs, including mdma. the form of talk therapy used in the mdma sessions also troubled some on the panel who noted there wasn’t strong data to support its use outside of the trial. “the psychological intervention is still for me a bit of a black box,” said dr. paul holtzheimer with the national center for ptsd. “what was described is really a relatively vague, ill defined treatment.” some of the strongest arguments for approval came from patients who spoke during the public comment period about the urgent need for an effective treatment. some had taken part in the mdma trials and said they found the medication to be transformative. “i was fortunate enough to enroll and get accepted, ultimately changing my life forever,” said nick brown, a military veteran from colorado, who described how the treatment gave him self compassion and allowed him to “get better sleep, have better relationships, and live what feels like a completely new life.” other groups representing veterans echoed these sentiments. “i fear what will happen to them if this therapy is not approved,” said jonathan lubecky, a veteran who underwent mdma assisted therapy ten years ago, “imagine how many lives your vote could save. imagine how many will be lost if you did vote against this vital therapy.” but for all the promising anecdotes of recovery, there were also many involved in psychedelic research who raised concerns about how the trials were run and the persistent problems in the data. some of the harshest criticism came from several researchers who had initially petitioned the fda to hold the public hearing, including neşe devenot, a researcher at johns hopkins university, who said the model of therapy “incentivized boundary violations.” data shared from lykos showed a range of adverse events. the majority of those in the study had a history of suicidal ideation in their lifetime, but during the study period “the frequency of these symptoms was comparable between the two groups, said dr. alia lilienstein, senior medical director for lykos therapeutics. “of note there were no suicidal behaviors or attempts reported in the mdma group,” she said. that point is particularly contentious because of recent allegations that certain adverse events were not reported. the petition calling for the advisory meeting outlined these concerns and others, citing an unnamed former employee of the drug company. there is already a well documented case of two therapists in the phase 2 trials with a participant who said they engaged in inappropriate contact with her while she was under the influence of mdma. the videos of the two therapists in bed with the participant were eventually made public by a podcast. “let's try to not gloss over this misconduct. it was sexual misconduct. that's particularly important,” said joniak grant, a sociologist and a member of the panel. several other panelists asked questions about the potential that mdma, once available widely in therapeutic settings, could lead to other instances of unethical behavior. last month, a report from the institute for clinical and economic review, a group that evaluates clinical data and drug prices, concluded there was insufficient evidence to assess the overall net benefit of mdma assisted therapy, after a lengthy investigation into the trial data. that report stated that it’s possible those involved in the trials including therapists and investigators encouraged the reporting of positive events and downplayed adverse events. the drug company has pushed back on the allegations and said it stands behind the data. a public comment submitted to the fda by one trial participant said her therapist encouraged her to view “worsening symptoms as evidence of healing and ‘spiritual awakening’” and that she and other participants later struggled with suicidality following the trial. when asked if some participants may have been discouraged from participating in the long term durability study, lillenstein said those claims had been investigated. “all participants who were interested in participating were given the opportunity to review consent, and some chose not to participate after reviewing consent, but otherwise everyone was given the opportunity,” she said. an earlier version of this story said that mdma is a schedule iii drug. in fact it is a schedule i drug. sponsor message become an npr sponsor

a vote against using mdma as part of therapy for ptsd has provoked a powerful backlash among researchers who study psychedelic drugs. some 13 million americans struggle with post traumatic stress disorder (ptsd). existing therapies only bring relief for a fraction of patients, and new treatments are sorely needed, according to psychiatrists wrestling with the scale of the problem. so, there was distinct disappointment when an advisory committee at the us food and drug administration (fda) voted earlier this month against a therapy that many had hoped could offer the first new treatment for ptsd in 25 years. a number of experts who study psychedelics have since spoken out in support of mdma assisted therapy for ptsd and have sharply criticised the recommendations of the fda's psychopharmacological drugs advisory committee. but some are still optimistic that the treatment might be approved when the fda delivers its final decision in august. while mdma, also commonly known as ecstasy or molly, is listed as a schedule 1 controlled substance in the us and so is illegal to use outside research, there has been a growing number of studies suggesting that when used with psychotherapy it could have potential for treating ptsd and some other mental health conditions. ahead of the meeting, fda approval of mdma assisted therapy for ptsd seemed likely, says sandeep nayak, an assistant professor of psychiatry at johns hopkins university, who investigates psychedelics as treatments for substance use and mood disorders. about two thirds of people who received three sessions of mdma and talk therapy no longer qualified for a ptsd diagnosis at the end of two phase 3 clinical trials. it's an outcome that is "almost double that of existing medications", says gül dölen, a neuroscientist at the university of california, berkeley, who researches the mechanisms of how psychedelics achieve therapeutic effects. "what's more, [the treatment] led to durable improvements in these patients lasting at least six months." about half of people who enroll in current gold standard ptsd treatments drop out, which is "absurd", says loree sutton, a psychiatrist and retired brigadier general in the us army. she says new treatments are essential. "we have to do better." "even if there are risks, we've got to figure this out, because we cannot not let this treatment be available," adds rachel yehuda, a professor of psychiatry and neuroscience at the icahn school of medicine at mount sinai who has conducted studies on the effects of mdma assisted therapy for ptsd. "without it, we're just leaving too many people in suffering that they don't need to be in, and that is not right." the fda is currently considering an application from california based drug company lykos therapeutics for using mdma capsules taken in conjunction with therapy in the treatment of ptsd. in the recent fda advisory meeting, committee members cited apparent flaws in study design and data collection. the nine hour hearing concluded with committee members voting 9 2 that the available data do not show "that the drug is effective" for ptsd, and voting 10 1 that the benefits of mdma do not outweigh the risks. the vote has highlighted some of the complexities that regulators face when evaluating psychedelic therapies. critics point out that just one member of the fda advisory committee had expertise in psychedelics, and argue that the committee may have misunderstood aspects of the treatment. "there are so many different issues and angles to this dumpster fire, which indeed i would say it is," says franklin king, a psychiatrist at mass general hospital and harvard medical school, who is overseeing a study of psilocybin assisted therapy for irritable bowel syndrome and another of mdma assisted therapy for fibromyalgia. "the biggest issue is that the advisory committee members really showed a kind of astounding lack of knowledge about the subject matter." the panel spent some time, for example, debating whether it should be voting on efficacy and safety of "the drug" or the drug assisted therapy model that the clinical trials investigated. excluding the therapy from the efficacy evaluation "doesn't make sense, scientifically speaking", says eduardo schenberg, director of the instituto phaneros, a psychedelic research and therapy group in são paolo, who has conducted research into mdma assisted psychotherapy for victims of sexual abuse with severe ptsd. the bbc contacted the 11 committee members asking if they had any response to the criticisms raised by researchers quoted in this article. one member, kim witczak, a drug safety advocate and the committee's consumer representative, replied. "this is a new territory and it must be treaded carefully," she wrote in an email. "the time to be cautious is now, not afterwards." the committee's vote is non binding, but it could influence the fda's decision to approve the treatment, which will be announced by august 11. historically, the fda has declined to approve 67% of drugs that received a negative vote by its advisory committees. an fda spokesperson declined an interview request, citing the application's pending status. but below are the main areas of debate raised by the committee surrounding the treatment, and why many experts believe it might still be approved. from the start of the meeting, committee members expressed concern about whether they could trust the trials' positive results. a primary issue was functional unblinding, or the ability of participants to tell whether they received a placebo or active drug   which has the potential to influence the outcome captured in the data. more than 90% of people in the mdma group and 75% in the placebo group correctly guessed their treatment arm in the second phase 3 trial. functional unblinding has been debated in the scientific literature for decades, sutton says, and occurs particularly in interventions that produce strong effects. but it's especially pronounced in studies of drugs with psychoactive effects. "we all struggle with these design problems," says harriet de wit, a professor of psychiatry and behavioural neuroscience at the university of chicago who has conducted extensive research on mdma and other psychoactive drugs. "they're insoluble." the fda is aware of the challenges and intricacies of mdma assisted therapy, says amy emerson, the chief executive of lykos therapeutics. she says the agency has been working with her company and its parent non profit, the multidisciplinary association for psychedelic studies (maps), on trial design for around 20 years. "it's almost like this came as a total surprise that this was the study design, when in fact the fda approved this design," says natalie gukasyan, an assistant professor of psychiatry at columbia university irving medical center, whose research focuses on understanding and optimising the safety and efficacy of psychedelic assisted therapy. according to nayak, the fda itself has said that a trial can be well controlled even with unblinding. in the case of mdma assisted therapy, "i do not think unblinding alone could explain the magnitude and durability" of the findings, he says. in his view, the treatment seems "efficacious". in the committee meeting, however, paul holtzheimer, the deputy director of research at the us department of veterans affairs' national center for ptsd and a professor of psychiatry and surgery at dartmouth geisel school of medicine, said he was "unconvinced by the acute efficacy of the treatment", as demonstrated by the data reported in the phase 3 trials. "the difference between the active and the placebo group is statistically significant by [the authors'] analyses, but relatively small enough that i think the role of expectation bias cannot at all be discounted as potentially accounting for a lot of that difference." another issue the committee raised was the fact that 40% of participants had taken mdma before   mostly on the order of two to four times in the past 10 years, emerson says. the committee expressed concerns that people who had sought out the illegal drug likely had a more favourable view of it going into the trial, which could introduce positive bias. but the data reported in the studies revealed no statistical differences between those who had and had not tried mdma before, emerson says. people who have tried mdma outside of a legal, medical setting are also a "normal part" of the population, she adds, so "it felt valid to enroll that group". evidence suggests that mdma assisted and other psychedelic assisted therapies work by reopening critical periods   finite windows of malleability when the brain is primed to learn new things. dölen has found that critical periods only reopen when a psychedelic drug is given in a particular setting. in the case of mdma for treating ptsd, that setting is psychotherapy. this would explain why people who take mdma at raves usually do not report spontaneous recovery from ptsd, dölen says. and it probably also explains why clinical trial participants experienced such "remarkable" improvements: they are literally rewiring their brain. among the questions asked by the advisory committee, however, was why mdma was not given to subjects on its own, without any therapy. dölen believes this may betray a lack of current scientific understanding of how the treatment works. "without the biological mechanism to ground them, i think the advisory committee felt a little insecure about believing the data from the clinical trials." while psychotherapy falls outside the fda's regulatory duties, it was the subject of much discussion in the committee meeting. walter dunn, a psychiatrist at the veterans administration greater los angeles healthcare system and the university of california, los angeles, and the fda committee member who has studied psychedelics, said in the meeting that the use of psychotherapy is both the "greatest strength" and also the "greatest liability" of the treatment. several committee members raised concerns that talk therapy was not standardised across clinical trial sites. lykos therapeutics insists it took "significant steps" to ensure consistency. but as king points out, talk therapy in general is not regulated at the federal or state level. "there's professional organisations that set guidelines, but you're not prevented from deviating from them as long as you don't do anything unethical." he adds that if talk therapy standardisation is "a deal breaker issue, then it'll affect every psychedelic". the potential for mdma therapists to abuse patients came up as well. one participant from the phase 2 clinical trial did experience such a violation, which lykos reported to the fda, health canada and the trial's intuitional review board. "it's absolutely unacceptable that someone was harmed and there was sexual misconduct," says emerson at lykos. however, while "very serious" and "very unfortunate", the issue of therapist misconduct falls to those who regulate practitioners, says wim van den brink, an emeritus professor of psychiatry and addiction at the university of amsterdam. but it shouldn't be a reason to halt approval of an efficacious treatment, he says. in future trials of psychedelic assisted therapy, gukasyan says, it might be preferable for pharmaceutical companies to work with professional societies to train and vet therapists, rather than oversee that part of the process themselves. the committee also raised questions about whether people who take mdma in a clinical setting might develop an addiction afterward. van den brink says this is not based on reality: mdma's primary effect is on serotonin, with a significantly lesser effect on the brain's dopaminergic system and little if any effect on the opiate system. people who take it too often also quickly develop tolerance due to serotonin depletion. "here in the netherlands, people have been using ecstasy for the last 40 years and we don't see anyone in addiction treatment for it," van den brink says. "most mdma users take one or two mdma pills once or twice per year." although some side effects have been reported in mdma assisted psychotherapy, they have been deemed "largely transient and mild or moderate in severity", according to one systematic review of clinical trial studies. most of those reported consisted of blurred vision, muscle tightness, decreased appetite and dilated pupils. in the phase 3 trial, three participants experienced serious suicidal ideation during treatment, but they were split between those who received mdma and the placebo. seven participants also experienced cardiovascular issues such as faster heartbeats, suggesting that older patients or ones with known heart problems might need to consult a cardiologist before undergoing the treatment. committee members also flagged a lack of certain data collected by lykos, including electrocardiograms and liver function, and participant feelings of euphoria. it has led to a characterisation of the clinical trials as "flawed". according to gukasyan, though, "every study will have limitations, so basically every study is flawed" if that logic is followed. several members of the public also alleged in video or written testimony that clinical trial data were tampered with to appear more positive and to exclude adverse events. "i was just as concerned as anyone hearing those reports, and they'll have to be objectively evaluated," sutton says. "but i have no reason to believe that there's been systemic malfeasance." "despite some very loud noise, we have yet to see any credible evidence that research misconduct occurred in phase 3," king adds. he fears, however, the "air of controversy" may have influenced some committee members. lykos takes allegations of misconduct "very seriously," emerson says, and investigates them all. the fda is also conducting its own routine inspection process to validate its view of the data, she adds. despite the meeting's outcome, the experts who the bbc spoke to believe there is still a chance that the fda will grant approval in august. emerson also remains hopeful. "the same things we needed to do before the [meeting] are the same things we need to do now, they're just a little more difficult and more public," she says. "we really believe in the fda's ability to assess the information and go through their process." given the fda's long involvement with the trial design, the strength of the data and all that's already known about mdma, denying approval would "look a little ridiculous for the fda", van den brink says. "i don't think the fda will follow [the committee's] advice." a negative decision from the fda would also likely impact on other studies of psychedelic assisted therapy that are currently in the pipeline, gukasyan says. "though this is one drug from one company and others have handled their clinical trials differently, some of the concerns brought up at the advisory committee meeting are likely to affect nearly every other psychedelic [trial]   namely, the psychotherapy component and concerns about blinding," she says. "it is important that regulators achieve clarity and consensus on how they understand and evaluate these issues moving forward." a rejection of mdma assisted therapy would also send "a very strong message" that psychedelic trials should focus on the effects of the drug alone rather than on the drug therapy combination, king says   an approach that "fails millions of people". "this whole episode only serves to reinforce the idea that anything that actually is a paradigm shift just doesn't fit into our regulatory system," he says. if the agency does wind up denying approval, van den brink adds that the netherlands could beat the us in becoming the first country to undertake a largescale, controlled rollout of mdma assisted therapy. (while australia recognized mdma as a medicine last july, its special access programme requires cumbersome permissions on an individual patient basis and only a few patients have received treatment, he says.) days after the fda committee decision, a panel of dutch experts issued a plan for a "naturalistic study" that, if approved, would provide mdma assisted therapy to 400 to 500 people with ptsd within the next five years. as van den brink says, "we shouldn't leave patients with very serious problems on their own because a study is not perfect."    if you liked this story, sign up for the essential list newsletter   a handpicked selection of features, videos and can't miss news, delivered to your inbox twice a week. dr. lisa dahlgren discusses the effect human touch has on our health and wellbeing. a new study says patients are less likely to die in the care of female physicians. researchers believe the ability to predict the future is a skill that can be learned and developed. do certain personality traits mean some people are hard wired to be 'punctually challenged'? can we trust our memory? erm, no. max tobin explains how the peak end rule distorts how we remember our past. the first pill to treat postpartum depression is here. does it have risks? as the planet continues to warm, this summer could be the worst yet for tick borne infections like lyme disease. in the basement of a university in denmark, is the world’s largest collection of human brains. dr julia shaw shares psychological tips and tricks in tackling and taming your worst memories. do social media, some common assumptions and two scottish women hold the answers? why is fentanyl overdosing and killing americans while being a safe and approved medicine? how did patty hearst become a symbol of the violent radicalisation of youth in the 1970s? illeism is a tool that might clear your mind from indecision. how does it work? gen z may lead the way when it comes to a healthy lifestyle, but is gen z the healthiest generation overall? with all the advantages of the modern world, which generation is the healthiest? how was stockholm syndrome invented 50 years ago and why is it problematic? former politician rory stewart shares his top tips for having great arguments. our brain constantly interprets the information it receives from the world. what happens in our brains when our strongly held beliefs are challenged? is it possible that some people are more vulnerable to conspiracy theories? or are we all at risk? treatments are the same as cancer sufferers but they don't receive the same support, a mother says. jack percival is trekking 400 miles to glasgow on a journey sparked by his own challenges. "things are worse now than 30 years ago... that's a horrible observation," says retired gp. the average number of women being tested in cambridgeshire is failing to hit the national target. after being struck down by winter illness, the bbc's james gallagher goes in search of ways to boost his immune system. copyright 2025 bbc. all rights reserved. the bbc is not responsible for the content of external sites. read about our approach to external linking.

news article author(s): follow hcplive's coverage of the full day fda committee meeting regarding lykos therapeutics' application for mdma assisted therapy as a novel treatment for patients with ptsd. the us food and drug administration (fda) psychopharmacologic advisory committee (pdac) voted 2 9 against supporting the effectiveness of mdma in the treatment of adult patients with ptsd, relative to clinical trial data from the mapp1 and mapp 2 trials sponsored by lykos therapeutics. the decision is anticipated to influence the final fda decision on the company's new drug application (nda) for mdma assisted psychotherapy for the treatment of adults with ptsd, which is scheduled for final decision by mid august this year. the committee additionally voted 1 10 to reject that the benefits of mdma in combination with the fda’s proposed risk evaluation and mitigation strategy (rems) outweigh its risks for the treatment of patients with ptsd. below is a live report of the fda pdac meeting as covered by hcplive. 5:20 pm et update following the public hearing session, the pdac reviewed the discussion questions itemized for the conclusion of the meeting. here are summaries of their perspectives. question 1: discuss the evidence of effectiveness for mdma for the treatment of ptsd. panel members including walter s. dunn, md, phd, assistant clinical professor at university of california los angeles, largely highlighted concerns with the functional unblinding of the the pivotal mapp1 and mapp2 trials and participating therapists, in which mdma assisted therapy was compared to placebo in the treatment of ptsd. jess g. fiedorowicz, md, phd, head and chief of the department of mental health at the ottawa hospital, highlighted the high level of patient engagement, endorsement, and limited dropout surrounding the clinical trials; however, these factors again may have been influenced by the functional unblinding, fiedorowicz said. he echoed other colleagues in expressing concerns over public hearing comments regarding trial research misconduct as it related to treatment outcomes. paul e. holtzheimer, md, ms, deputy director for research at the national center for ptsd, noted a particular issue with the available data is that lone psychedelic therapy is not evidenced beyond the support of successive psychotherapy; it remains an investigative therapy in the scope of the research. question 2: discuss whether the available data are adequate to characterize the safety of mdma for the treatment of ptsd. sentiments from the committee reflected concerns around the available safety data beyond the acute treatment stage, particularly in continued mdma assisted psychotherapy sessions beyond the tested 3 session regimen. experts believed the cardiovascular and blood pressure related outcomes observed in the phase 3 trial could be potentially mitigated by the fda's proposed rems. additionally, unreported adverse events potentially tied to the psychotherapeutic effects of mdma were frequently raised as an issue by committee members. question 3: discuss the potential for patient impairment to occur with mdma and the potential for serious harm that may result due to the impairment. dunn mentioned the risk of patients being coerced and/or manipulated in the acute and sub acute stages of care, with regard to the "openness" effect associated with mdma warranting a review and monitoring of that outcome going forward. additionally, he posited whether patients would be recommended to safely titrate other psychiatric therapies if eligible for mdma assisted therapy, and whether such a recommendation would be associated with any adverse event risks from coming off current medication. he and other colleagues also expressed interest in more formally setting precedent for which licensed, qualified care providers are involved in the acute care and monitoring settings. elizabeth rebo, pharmd, executive director of pharmacy quality and medication safety at kaiser permanente, questioned the ability to enforce consistent guidance on protocol to discharge a patient from outpatient care and allow them to eventually operate a vehicle after mdma administration. other colleagues expressed concern over fall risks and other physical incapabilities post treatment. question 4: discuss whether the proposed risk mitigation is sufficient to mitigate serious harm resulting from patient impairment. include any additional safety monitoring conditions needed for the safe administration and monitoring of mdma if approved for ptsd. melissa d. barone, psyd, adjunct assistant professor of psychiatry at university of maryland school of medicine, expressed the want for care provider education both from psychedelic therapy experts who are uninvolved with the drug sponsor, and with regard to potential non psychiatric health risks including how to manage a patient with raised blood pressure post mdma dose as observed in some patients in the mapp1 and mapp2 trials. other comments noted the difficult to adequately comment on the proposed topic without more substantial evidence surrounding the duration and characteristics of mdma psychoactive effect on treated patients. experts also expressed interest in more opportunities for third party reporting centric for patient reported outcomes and their issues with acute care. the subject of frequent video monitoring of psychotherapy sessions, raised also during public hearing sessions, were an expressed interest from the committee. 3:45 pm et update brett waters, an attorney and cofounder and executive director of non profit advocacy group reason for hope, shared his familial history with suicide, including his mother and grandfather, the latter being a world war ii veteran. waters described the potential aversion patients with psychiatric illness may have with ssris that are the currently lone fda approved therapies for ptsd. “i appreciate the thoughtful questions the committee has asked in evaluating this very challenging and novel application, however i urge that you not lose the forest through the trees,” waters said. “mdma assisted therapy offers a seemingly obvious and logical approach to ptsd treatment, as the drug’s ability to rapidly establish therapeutic rapport and reduce fear response makes it easier to commit to and engage in a psychotherapeutic process that involves confronting often highly traumatic memories.” brian pace, phd, a lecturer in psychedelic studies in the department of plant pathology at the ohio state university and coauthor of a citizens petition raising concerns with lykos’ nda, echoed comments criticizing the conduct of the clinical trials and “dubious, grandiose” claims of the ultimate benefit of applied psychedelic therapy. rev. joe welker, a pastor at east craftsbury presbyterian church and self described whistleblower on the psychedelic industry in his prior work with johns hopkins university raised issues with the “spiritual and religious conflicts of interests” pertinent to the background of the research’s development. a self described patient who said they underwent a single round of mdma assisted therapy to treat their ptsd in a clinical trial earlier this year, said the experience has “completely derailed” their life, including symptoms of exhaustion, cognitive impairment, brain fog, headaches, and more. deran young, a licensed therapist and founder of black therapists rock, positively described her experience with mdma assisted psychotherapy specifically for the treatment of racially based trauma. naomi mathis, assistant national legislative director at disabled american veterans (dav), emphasized “the need for innovation” in ptsd care for impacted veterans; she called the mdma assisted therapy data for such patients “promising.” “while dav does not take a stance on the state of the science, we are heartened to see such research take place,” mathis said. all available public hearing comments are available to watch here. 3:15 pm et update the afternoon portion of the committee meeting agenda opened with public comments. brian dempsey, government affairs director at the wounded warrior project, spoke positively on the adoption of mdma assisted psychotherapy for the treatment of veterans with ptsd. a significant majority of veterans experiencing trauma primarily seek care through the veterans affairs (va) program, dempsey said, though they can experience longer wait times, provider churn and emphases on prescription medication through the va. “all of these points underscore how increasing demand, unique interaction with the healthcare system, and willingness to try new approaches when others aren’t working are extremely present factors for veterans suffering from invisible wounds of service,” dempsey said. he quoted a veteran who received mdma assisted care through their network, who advocated for its effectiveness in helping them to regulate and process their emotions. “we believe there are still important considerations about patient education, treatment scalability, and impact on employment that need to be addressed, but we are wholly committed to finding new options for care for veterans who want and need care that they deserve,” dempsey said. robert m. grant, md, mph, professor of medicine at university of california san francisco, previously sponsored by lykos 2 years ago, discussed his experiences as a trained mdma assisted therapy care provider and the importance of managing ptsd particularly as it relates to mitigate its effect on the prevalence and exacerbation of chronic, severe conditions. he noted the frequency of underlying ptsd in patients in emergency care settings is higher than most would imagine: a patient with liver failure due to an alcohol use disorder spurred by trauma, or a patient with cardiac failure due to excessive tobacco use driven by ptsd, among others. these don’t also speak for patients being treated for suicide attempts due to their ptsd. “ptsd is an underlying driver for much of our disease burden broadly, and existing therapies for ptsd are relatively ineffective and poorly tolerated, with less than 5% of the affected population being willing to start and complete the current standard of care,” grant said. “i find the (lykos mdma assisted therapy data) evidence to be convincing and compelling especially when combined with the substantial phase 2 program…not being discussed in this meeting.” russell hausfeld, a journalist with psymposia, raised concerns regarding potential exploitation and mistreatment of veteran patients involved in clinical trials with the company. next, a self described veteran of the iraq war with ptsd described how the condition impacted his mental, emotional, social and professional wellbeing. the veteran described undergoing a number of therapies, practices and resources to alleviate his symptoms to no significant benefit; he described suicidal ideation at a point when he believed his ptsd couldn’t be effectively treated. “i cannot put into words how much this drug assisted therapy helped me when i got into (the trial),” the veteran said. “the parts of me that i thought were permanently damaged the way i saw the world and my response to stimuli had changed. the innocuous sounds and actions that you guys would not notice, that used to fill me with rage, anger, fear, anxiety and shame, they now go by so unnoticed that i feel normal.” nese devenot, phd, senior lecturer at johns hopkins university and coauthor of a citizens petition to extend the open public hearing, said she believes lykos “obscured its actual intervention” in the fda submission, calling for an independent review of all relevant clinical trial video recordings observing the dosed patient clinician interaction. michael abrams, mph, phd, senior health researcher from the public citizen’s health research group, further discussed the “functionally unblinded” nature of the mapp1 and mapp2 trials and its possible influence toward favorable drug effects. “patients and therapists likely knew who received the drug, and anecdotes suggest some therapists abused that knowledge to manipulate patient beliefs,” abrams said. jonathan alpert, md, phd, chair of the department of psychiatry and behavioral sciences at albert einstein college of medicine and chair on the council on research at the american psychiatric association, stressed the unmet therapeutic needs of the approximate 13 million us adults with ptsd; however, he also expressed caution behind the prospect of treating with mdma. “mdma represents a promising treatment for a devastating illness however, there are significant limitations to the current evidence base on mdma for ptsd,” alpert said. albert cited the clinical trial data’s functional unblinding, the high rate of lifetime mdma use among study participants, the nature of the time intensive novel psychotherapy session, and the currently limited long term data regarding safety outcomes and ptsd relapse rates beyond 2 months post treatment. “the apa supports research and therapeutic discovery into psychedelic agents that’s pursued with the same scientific integrity, rigor and regulatory standards applied to other promising therapies in medicine,” alpert said. ifetayo harvey, executive director of the people of color psychedelic collective, criticized the inadequate inclusion of non white trial participants. kayla greenstein, a phd candidate from the university of sydney, expressed concern with the theoretical underpinnings and the “use of touch” in psychedelic therapy sessions. greenstein additionally called lykos’ statement that mdma facilitates memory recollection a “highly controversial idea.” 12:40 pm et update victoria sammarco, pharmd, mba, a risk management analyst for the center for drug evaluation and research (cder) at the fda, provided a detailed overview of the fda’s proposed risk evaluation and mitigation strategy (rems) for the application of mdma assisted therapy to treat patients with ptsd. a full description of the fda’s rems proposal can be found below today’s updates. the components of an fda rems plan can include medication guides or patient package inserts; communication plans for healthcare providers; packaging and safe disposal technologies; elements to assure safe use (etasu); implementation systems; and timetables for the submission of relevant assessments. among the risks associated with mdma for which the fda is considering a rems are the effects linked to illicit mdma (ecstasy) use, including: such effects could put patients at risk of hospitalization, death, or other events of significant consequence. “the agency’s rationale for our proposed rems is rooted in the patient impairment expected from mdma administration, and the need to ensure patients are safe from serious harm from impairment,” sammarco said. “the agency’s proposed rems is informed by the strict controls that were in place during clinical development." such controls included the following: the proposed rems goal, sammarco said, is to mitigate “serious harm resulting from patient impairment from mdma administration by ensuring that during and after mdma administration, patients are managed in a medically supervised healthcare setting.” 12:30 pm et update david millis, md, clinical reviewer in the division of psychiatry at the fda, provided a presentation on the agency’s assessment of mdma capsules relevant to lykos therapeutics’ proposed nda. in first reviewing the characteristics of ptsd, millis described it as a “disabling condition” frequented with intrusive memories, nightmares, hyperarousal and avoidant behavior following exposure to serious trauma including actual or threatened death, serious injury or violence including sexual assault. it is highly comorbid with mood, anxiety and substance use disorders, and may lead to significantly increased risk of suicidality. regarding mdma, millis described the drug’s chemical structure to ampehtamines, while its pharmacological mechanism acts as a serotonin, norepinephrine and dopamine reuptake inhibitor and releasing agent. the proposed dosage would be an oral option taken 3 times at least 3 weeks apart in a supervised treatment session over the course of 4 months. the add on psychotherapy course would occur in between medication administrations. only ssris paroxetine and sertraline are currently approved by the fda to treat ptsd, millis highlighted though both agents are limited by approximate 60% response rates, boxed warnings for suicidal ideation and behavior risks with ssris, and an incapability to treat the root cause of ptsd, only the symptoms. the proposed dosing regimen is as follows, with medication sessions occurring ≥21 days between one another: “the applicant is proposing a novel treatment paradigm,” millis said. “rather than a chronic daily administration, the proposed mdma regimen is more circumscribed. this time limited treatment is intended to provide lasting relief from ptsd symptoms.” regarding regulatory history and the key issues with the proposed drug, millis addressed the winding and complex background of the therapeutic development of mdma. first, he acknowledged the fda’s concern about potential functional unblinding, as stated by tiffany r. farchione, md, in her opening remarks. millis noted that at the end of lykos’ phase 2 trial, the fda suggested active comparators be used to limit the effect of functional unblinding (i.e., patients being aware they have received the psychoactive drug instead of placebo). they recommended comparators including niacin or lower dose mdma. millis said the company and the fda did not reach an agreement on the adequacy of the blinding process during this 2016 meeting, with lykos stating niacin may worsen ptsd symptoms, while lower dose mdma could exacerbate anxiety in some trial participants. “we rely on data from adequate and well controlled trials to provide the basis for a substantial evidence of effectiveness,” millis said. “among other characteristics, to be considered adequate and well controlled, a study must incorporate a design that permits valid comparison with a control condition, and measures must be taken to minimize bias.” in the specific case of comparing mdma to placebo for the treatment of ptsd, millis explained, a patients’ awareness that they are receiving the psychoactive drug may positively influence their treatment while the disappointment a patient feels in realizing they are in the placebo arm may harm their treatment process. next, millis reviewed prior discussions with the company’s submission for a special protocol assessment (spa) for the phase 3 mapp1 trial in 2017. spas are a process in which individual new drug (ind) applicants try to reach an agreement with the fda on the design of a study intended to support an eventual marketing approval. by march 2017, an spa no agreement letter was issued, millis said, with disagreements between the agency and company on the proposed statistical analyses and choice of secondary endpoint in mapp1 (see below). there was agreement, however, on the company’s plan to minimize bias via blinded centralized independent rater pools to administer the primary outcome measure via video interviews, as well as the use of mdma assisted therapy as the mapp1 treatment arm, versus identical psychotherapy with inactive placebo serving as the control. the fda and company additionally agreed on the established definitions for treatment response, loss of ptsd diagnosis, and remission per in clinician administered ptsd scale for dsm 5 (caps 5) (see dsm diagnostic criteria for ptsd below). additionally, the no agreement letter from the fda stated that all phase 1   3 clinical trials must document adverse events associated with potential abuse or overdose in mdma treated patients. it additionally stated that all clinical safety and efficacy trials should be evaluated for central nervous system (cns) related adverse events “that may suggest the test drug produces effects that will be sought out for abuse purposes.” similar to farchione, millis highlighted the agency’s request for data regarding the presence of “euphoria like response” to help interpret the potential for abuse of a clinically tested drug. “however, in reviewing the clinical study reports submitted with the application, we noticed a striking lack of abuse related adverse events,” millis said. “when we followed up the applicant about their abuse potential assessment methodology, they clarified that they did not systematically collect abuse related adverse events in the guidance. rather, they only documented events identified as unfavorable.” millis said it is a “major concern” that this evidence in missing in the regulatory application for mdma, saying it would serve as key data to help characterize the cns effects of the drug. “as a result of not having this data, our ability to properly describe the expected severity and frequency of these events in product labeling is affected,” he said. the fda is also without adequate data that would help to inform the duration of mdma effect that would help clinicians safely discharge their patients, as well as to help the agency appropriately describe the effects of the drug in potential labeling. among the other events of note in the regulatory history of lykos’ nda application, millis highlighted the granted breakthrough therapy designation for mdma as a ptsd treatment based on phase 1 and 2 data in august 2017; the company’s agreement to the fda’s recommended participant blinding survey for mapp2 in october 2020; and lykos’ agreement to submit said survey results in accompaniment with the nda submission in may 2023. the fda stated the unblinding survey results from mapp2 showed that most trial participants could adequately guess which treatment arm they were randomized to. millis additionally reviewed the proposed psychotherapy intervention component of the indication, as per the maps manual for mdma assisted psychotherapy in the treatment of posttraumatic stress disorder. he noted the guide provides general principles on therapeutic approach among treated patients, giving the therapist flexibility to choose therapeutic modalities with which the therapist is familiar. “the content or the approach of these integrated sessions was not standardized in the treatment manuals, and was left up to the individual therapist…and could vary considerably from therapist to therapist,” millis said. in reviewing the phase 3 findings from mapp1, mapp2 and the observational follow up mplong trial, millis noted that the fda agreed to lykos’ proposed threshold of ≥10 point change on caps 5 score denoting ptsd response. descriptions of the mapp1 and mapp2 trial findings are posted below. regarding safety outcomes from the pivotal trials, millis noted the risk of rapid elevation in both heart rate and blood pressure was highest among patients with preexisting cardiovascular disease; however, only 6.1% of patients receiving mdma in the trials reported a systolic blood pressure of >180 mmhg following their dose. millis did note, however, that mdma may include potential for proarrhythmic outcomes based on trial data. suicidal ideation and behavior was not evidently increased in the immediate 24   72 hours following mdma dosing sessions, despite the known heightened risk of such conditions in patients with ptsd, millis said. he also noted that some of the adverse events related to the stimulant or serotonergic properties associated with mdma may include insomnia, sleep disorders, anxiety, restlessness and nervousness. millis provided further details on the abuse potential of mdma, highlighting a review from the fda controlled substance staff that which suggests mdma has abuse potential that parallels schedule ii stimulants including morphine, oxycodone and methyphenidate. the agency did not require lykos to perform a dedicated human abuse potential study due to sufficient published literature on the subject already. “overall, the safety profile for mdma observed in the development program is consistent with its known effects,” millis said. “however, certain risks cannot be fully characterized based on the safety data from this program.” the “relatively small safety database” from the mapp trial program may be acceptable if fda can agree that the proposed 3 dose time limited treatment regimen of mdma assisted therapy is indeed effective and durable for the treatment of ptsd, millis said. 11 am et update kelley o’donnell, md, phd, research assistant professor of psychiatry at nyu grossman school of medicine and director of clinical training at the nyu langone center for psychedelic medicine, provided a clinician’s perspective on the available clinical efficacy and safety data supporting lykos’ fda application. o’donnell said her interest in the mounting evidence supporting the proposed indication piqued with data showing the drug may catalyze the effects of psychotherapy a far cry from the lessons she learned only about mdma’s harmful effects in medical school. she echoed lykos representatives’ sentiments regarding unmet needs for the ptsd patient population (below update), highlighting the combined issue of limited efficacy with psychotherapy and ssris plus increased patient risk of severe outcomes including suicidality. “we generally don’t think of psychotherapy as a rapid acting treatment for ptsd,” o’donnell said. “one challenge in trauma treatment is the therapeutic processing of traumatic memories can only happen when a patient feels safe. but many patients with ptsd move through the world feeling fundamentally unsafe in their own bodies and in their relationships with others.” this, o’donnell explained, is why the relatively rapid results of mdma assisted therapy in clinical trials has been such a “rewarding” outcome for her and her peers. o’donnell described the benefits of mdma on psychotherapy as four fold. o’donnell additionally noted that patients with meaningful reduction of ptsd symptoms from mdma assisted psychotherapy also experienced functional improvements: they had greater capability to pursue personal goals and maintain meaningful relationships. even patients with residual symptoms of ptsd after treatment generally were able to process trauma at the end of the regimen, reporting greater senses of safety, trust and self efficacy. “in this combination treatment, the acute effectiveness of mdma facilitates the psychotherapy strengthening the therapeutic alliance, facilitating the patient’s development of insights and tools, and continue to cultivate long after the acute effects are worn off,” o’donnell said. “i look forward to being better able to support my patients and those who care for them with this valuable and urgently needed care option for ptsd.” 10:30 am et update it has been 20 years since the fda has approved a drug for the treatment of ptsd. as lykos therapeutics representatives explained in the pdac meeting, there’s an even longer history of clinical utility of mdma that which be underreported. while introducing her team’s presentation of clinical data supporting lykos’ nda for mdma assisted therapy to treat patients with ptsd, amy laverdiere, mba, program lead at lykos detailed the clinical history of mdma in psychiatric care a history that is subjected to stigmatization by most laypeople. “mdma is not a new drug, and while it can be misunderstood due to its illicit counterpart, it actually has a well documented history in the psychiatric field,” laverdiere said. laverdiere detailed the use of the drug in the 1970s and 1980s in combination with talk therapy somewhat similar to lykos’ proposed use in combination with psychotherapy for patients with ptsd as well preliminary research from before that time showing the psychoactive drug can be beneficial for patients with psychiatric disease, particularly in helping patients to more adequately process, regulate and convey difficult emotions. lykos’ research involving 427 participants in 17 clinical treated with mdma is preceded by earlier work assessing the drug in approximately 4000 patients. “we know psychotherapy can be effective, but only if patients are able to tolerate the treatment,” laverdiere said. “the available data and mechanism of action suggest that mdma catalyzes the effectiveness of psychotherapy by facilitating memory recollection and extending the patient’s window of tolerance for revisiting distressing thoughts or experiences. studies of mdma show improved self awareness and pro social effects that enhance the therapeutic alliance between the patient and their therapist.” indeed, this mechanism of action would particularly benefit the unmet needs of patients with ptsd, who generally present with difficulties processing and deliberating on emotions in a way that may curb the benefit of standard care psychotherapy. jerry rosenbaum, md, director of the center for the neuroscience of psychedelics at massachusetts general hospital research institute, and stanley cobb professor of psychiatry at harvard medical school, followed laverdiere’s presentation with a lengthier review of the unmet needs of patients with ptsd a psychiatric condition estimated to affect approximately 13 million us adults. ptsd symptoms can last for, on average, 6 years; up to 3 in every 5 patients remain symptomatic despite their treatment, and half (48%) remain untreated altogether, rosenbaum explained. compared to those without ptsd, patients face a 47% greater risk of mortality, due to comorbidities including increased suicidality. “although ptsd is associated with exposure to deployment and combat, consequent to a number of potential experiences, civilian trauma is actually more common,” rosenbaum said. “individuals exposed to sexual violence, for example, or an unexpected death in the family or a life threatening traumatic event may also develop ptsd.” rosenbaum reviewed the dsm 5 criteria for ptsd, which includes the following: more simply, rosembaum explained, the condition may be characterized into 4 symptom clusters: avoidance of triggers; intrusion; negative thoughts and feelings; and arousal and reactivity. with current treatment options psychotherapy and selective serotonin reuptake inhibitors (ssris), there are apparent benefits and shortcomings with each. rosenbaum highlighted the clinically meaningful reduction of ptsd symptoms through psychotherapy, though also noted high rates of dropout due to exacerbated distress experienced by patients, as well as the limited access of the practice. with ssris, patient have been shown to experience greater improvement in clinician assessed scales for ptsd symptoms versus placebo  but response rates struggle to exceed 60%, and the drug class is only capable to target symptomology. "several pharmacologic agents are used off label and concurrently, despite lacking evidence of efficacy and not being approved for the ptsd indication which speaks to the demand from prescribers for novel indicated therapeutics to provide our patients new tools to alleviate symptoms,” rosenbaum said. lykos representatives further provided clinical efficacy and safety data supporting mdma assisted therapy from the phase 3 mapp trial program; you can find a summary of the trial’s findings below. 9:45 am et update tiffany r. farchione, md, director of the division of psychiatry in the office of neuroscience at the fda, provided the agency’s opening remarks earlier this morning. “this application is both consequential and complex,” farchione said. in reviewing the clinical program supporting the lykos therapeutics new drug application (nda) for mdma assisted therapy in the treatment of ptsd, farchione did acknowledge the mapp1 and mapp2 trials showed positive, clinically meaningful improvement of patients over short term periods findings that which were bolstered by long term, open label follow up suggesting a durable effect of mdma in treated patients. however, she noted as well that several factors impact the interpretability of these trial results. for one, the trial data are impacted by “functional unblinding,” meaning it is nearly impossible to blind studies due to the acute psychoactive effects of mdma. though the trials are designed and conducted in double blind design, participants are confident to guess their treatment assignment, which may influence expectation bias. potentially as a result, the follow up assessments featured a 25% participant dropout since the parent trial, and a trend of intercurrent, non study drug use among participants. additionally, farchione noted the poor characterization of psychotherapy in the clinical trials; the practice conducted concurrent with mdma administration was not compared in efficacy to any other method of therapy, and its clinical value in care for patients with ptsd was not observed with the addition of a lone mdma arm in the clinical trials. regarding the safety outcomes, farchione said mdma’s associated adverse events were consistent with the known effects of the drug; however, adverse events related to the potential for drug abuse were not adequately collected nor reported. “it is the lack of data collection on the subjective effects of mdma that may the greatest impact on our regulatory decision making,” farchione said. “although the agency had advised the applicant to collect adverse events that are associated with abuse effects that were deemed positive, favorable or neutral things like euphoria or elated mood were not captured, despite the fact that these effects are part of the evaluation of abuse potential, as we outline in our guidance on this issue.” farchione further explained subjective effects of mdma can persist for several hours, leaving patients impaired and in a vulnerable state. “if this product were to be approved, we believe the rems will be necessary to ensure safe use and to mitigate the risk of serious harm that can result from patient impairment.” “although this application presents a number of complex review issues, it does include 2 positive studies in which patients in the (mdma) arm experienced statistically significant and clinically meaningful improvement in their ptsd symptoms, and that improvement appears to be sustainable for at least several months after the end of the acute treatment period, despite no additional doses of (mdma),” farchione continued. farchione concluded by providing the 2 key discussion topics and voting questions each that will be addressed by the pdac. discussion 1: the evidence of effectiveness for mdma for the treatment of ptsd, with consideration toward the potential impact of functional unblinding on interpretability of efficacy results, the durability fo effect, and the role of psychological intervention in the treatment paradigm. discussion 2: whether the available data are adequate to characterize the safety of mdma for the treatment of ptsd, with consideration to limited data collected on events deemed positive, favorable or neutral that would inform the potential for abuse as well as lacking data from some clinical laboratory tests, as well as any other data related safety concerns characterizing mdma. voting question 1: do the available data show that the drug is effective in patients with posttraumatic stress disorder? voting question 2: do the benefits of midomafetamine with fda’s proposed risk evaluation and mitigation strategy (rems) outweigh its risks for the treatment of patients with ptsd? 8:00 am et update the us food and drug administration (fda) psychopharmacologic drugs advisory committee (pdac) meets today, june 4, to review the effectiveness of midomafetamine (mdma) for the treatment of patients with post traumatic stress disorder (ptsd).1 the meeting, scheduled from 8:30 am   5:30 pm et, will review the clinical efficacy, safety and known benefit risk profile of mdma as an add on therapeutic to psychotherapy in patients with ptsd specifically as evidenced in research conducted and supported by lykos therapeutics (formerly maps public benefit corporation) as part of their new drug application (nda) submitted to the fda for mdma assisted therapy to treat patients with ptsd. additionally, the pdac meeting will review a risk evaluation and mitigation strategy (rems) proposed by the fda to address the potential acute and long term safety concerns, as well as ethical risks, associated with providing the psychedelic therapy to patients with psychiatric condition. at the conclusion of the meeting, a vote will be called for the committee to vote on the following questions, as phrased in the agenda meeting draft made available prior to june 4: mdma is an oral, synthetic psychoactive compound that includes stimulant and psychedelic properties. previously studied and used in psychiatric practice about 5 decades ago,2 mdma was designated a schedule i drug by the fda in the 1980s, similarly to marijuana (cannabis) and lysergic acid diethylamide (lsd), among other drugs previously known for recreational misuse.3 however, the fda granted mdma breakthrough therapy designation in august 2017, on the basis of maps’ phase 2 trial data showing that 61% of patients with treatment resistant ptsd no longer qualified for their diagnosis after 3 sessions of mdma assisted psychotherapy.4 the clinical benefit of mdma in conjunction with psychotherapy appears to be the drug’s ability to “enhance the effects” of therapy itself in patients with ptsd.5 animal models have shown that mdma increases brain derive neurotrophic factor expression in the amygdala, which correlates with the eradication of fear memories. human neuroimaging studies additionally show mdma is linked to amygdalar bold activity reduction when presented with negative emotional stimuli. explained more succinctly by prolific investigator bessel van der kolk, md, to hcplive last week: “mdma really helped people to get in touch more with much more complex issues than the trauma.”6 “you have a much more complex set of mental problems besides the particular memory of the trauma,” van der kolk explained about ptsd. “and those set of mental functions really prevents people from getting better, because if you cannot control your emotions, you become extremely fearful when you start recalling the traumatic incidents. and you may actually freak out, shut down become very agitated you cannot go there.” in clinical trials, mdma doses has shown a capability to help patients with ptsd “go there” in concurrent psychotherapy sessions, leading to more beneficial outcomes. lykos’ nda is supported by findings from the follow up phase 3 program: a pair of phase 3 trials named mapp1 and mapp2, wherein participants with ptsd underwent 3 treatment cycles of mdma assisted therapy for 3 weeks each.5 investigators sought a primary endpoint in change in clinician administered ptsd scale for dsm 5 (caps 5) from baseline, as well as secondary endpoints regarding improvement in ptsd associated functional impairment from baseline, versus a placebo arm. investigators led by jennifer m. mitchell, phd, professor of neurology at ucsf weill institute for neurosciences, used a study drug manufactured by onyx scientific and compounded by sharp clinical services, in accordance with current good manufacturing practice (cgmp) standards. the team found that mdma assisted therapy was associated with significant attenuation of ptsd symptoms per caps 5 a mean change of  11.9 (95% ci,  6.3 to  17.4) in scores from baseline to 18 weeks among participants who completed the 3 course regimen versus the placebo arm (p <.0001). measures of clinician rated functional impairment per sheehan disability scale (sds) were also significantly improved in the mdma assisted therapy arm versus placebo ( 3.1 vs  2.0) during the same time period. additionally, investigators reported that 28 (67%) participants who completed the mdma regimen no longer met diagnostic criteria for ptsd at 18 weeks, versus 12 (32%) of the placebo arm after 3 psychotherpay sessions. another 14 (33%) of mdma treated participants met the criteria for ptsd remission after 3 sessions, versus 2 (5%) from the placebo arm. regarding safety, mild to moderate treatment emergent adverse events (teaes) that were more prevalent in the mdma arm than placebo included muscle tightness, decreased appetite, nausea, hyperhidrosis, and a sensation of cold temperature. investigators observed no increased aes relevant to suicidality, per columbia suicide severity rating scale (c ssrs), in the mdma arm. treated patients additionally reported a transient increase in systolic and diastolic blood pressure, as well as heart rate. interestingly, more than 90% of all trial participants reported suicidal ideation in their lifetime, and 17 (37%) patients in the mdma arm and 14 (32%) patients in the placebo arm reported suicidal ideation at baseline. mitchell and colleagues noted in their assessment of the findings that the effect size of 0.91 observed with mdma assisted therapy versus placebo was greater than that for any other pharmacotherapy assessed for ptsd “these data illustrate the potential benefit of mdma assisted therapy for ptsd over the fda approved first line pharmacotherapies sertraline and paroxetine, which have both exhibited smaller effect sizes in pivotal studies,” they wrote. “previous comparison of change in caps score between sertraline and placebo showed effect sizes of 0.31 and 0.37. similarly, comparison of change in caps score between paroxetine and placebo showed effect sizes of 0.56, 0.45 and 0.09.” the fda shared a draft of its rems proposal for mdma with the pdac meeting agenda, detailing recommended requirements, policies and resources that will work to “ensure the benefits outweigh the risks of serious harm resulting from patient impairment from (mdma) administration).”7 as they note, patient impairment is indeed an expected effect from the investigative therapy that requires safeguards promoting safety. in their rems proposal, the fda detailed that mdma may only be dispensed in certain health care settings, to patients with evidence or other documentation of safe use conditions, with each patient subject to monitoring and enrollment in a data registry. “the enrollment will inform patients about the risk of impairment and the serious harm that may result, the need to report adverse events, and the patient agrees to be discharged to an accompanying adult and not drive or operate heavy machinery in the immediate period after the medication session,” the statement read. additionally, healthcare settings would be required to develop and put in place policies and practices that ensure each of the following: regarding the proposed patient registry, the fda stated their proposed rems would ensure patient data collection will help to inform the agency of signs and symptoms from either mental or physical distress experienced by patients treated with mdma. it would also help to inform the fda on the onset and duration of short term effects of the drug, as well as whether care required escalation based on outcomes. “in addition, information regarding patient safety between treatments will be collected including events that result in increased risk due to impaired judgement, or worsening of psychological disorders that cause disability, hospitalization, or death,” the fda stated. “registry data will also be used to determine whether changes to monitoring and other safe use behaviors in the rems are needed.” references brensocatib, potential first treatment for non cf bronchiectasis, gets priority review medical ethics unpacked: glp 1 allocation and challenges of equitable access fda fast tracks car t therapy for lupus medical ethics unpacked: ethical considerations for euthanasia & medical assistance in dying researchers track sharp increase in diagnoses for sedative, hypnotic and anxiety use disorder in young adults children who experience a stroke have a greater anxiety risk brensocatib, potential first treatment for non cf bronchiectasis, gets priority review medical ethics unpacked: glp 1 allocation and challenges of equitable access fda fast tracks car t therapy for lupus medical ethics unpacked: ethical considerations for euthanasia & medical assistance in dying researchers track sharp increase in diagnoses for sedative, hypnotic and anxiety use disorder in young adults children who experience a stroke have a greater anxiety risk 2 commerce drive cranbury, nj 08512 609 716 7777

hand holding a pill against a psychedelic background/ taylor tieden for biospace after months of anticipation and lobbying by veterans and lawmakers, the fda late friday rejected lykos therapeutics’ new drug application for its midomafetamine (mdma) assisted therapy for post traumatic stress disorder. in its complete response letter (crl), the fda said the application “could not be approved based on data submitted to date” and requested that lykos conduct an additional phase iii trial to glean more information on the safety and efficacy of mdma. for its part, lykos intends to request a meeting with the regulator to “ask for reconsideration of the decision” and to seek fda’s recommendations for a resubmission. lykos noted in its press release that the issues raised in the crl “echo” those raised during the june meeting of the fda’s psychopharmacologic drugs advisory committee, which voted 10 1 against recommending the treatment. the committee members were particularly concerned about possible selection bias and functional unblinding, as participants could tell whether or not they’d been given the drug. in its press release, lykos said it “believes that the data included in the nda provide sufficient evidence of efficacy and durability in line with the relevant fda guidance.” originally published august 5, 2024 on aug. 11, the fda is expected to make one of the year’s most highly anticipated decisions: whether or not to approve lykos therapeutics’ mdma assisted treatment for post traumatic stress disorder. stakeholders and industry experts recently expressed concern over the therapy, with an advisory committee recommending against its approval. yet some are still optimistic about its potential particularly given the continued need for new treatments for post traumatic stress disorder (ptsd). there are currently more than 13 million individuals in the u.s. living with ptsd, many of whom are veterans or victims of domestic abuse. one of the major issues for this patient population is a stark lack of available and effective treatments. moreover, according to lykos, 40% to 60% of patients never achieve remission. the fda has not approved a new treatment for patients with ptsd in nearly 25 years. “given the high dropout rate with current therapies and the evident need for better treatments . . . i strongly believe that there is a consensus about need,” said jerry rosenbaum, a professor of psychiatry at harvard medical school. “the notion that mdma renders psychotherapy for ptsd to be more efficacious appears to have been demonstrated,” he told biospace. lykos is seeking fda approval to utilize mdma more commonly known as ecstasy as oral tablets to treat patients with ptsd, when combined with supportive mental health services like psychotherapy. “we believe that the agency sees there is a significant unmet medical need for those living with ptsd,” a lykos representative told biospace in an email. “we plan to work with top tier behavioral health centers that can meet the fda proposed patient monitoring requirements.” the representative added that if it is ultimately approved, lykos will consider studying the treatment in patients with other psychiatric disorders. lykos’ application is largely based on the results of a pair of pivotal phase iii studies, mapp1 and mapp2. in the mapp2 randomized, double blind study, investigators compared the treatment to placebo in 104 adults with moderate or severe ptsd who met full dsm 5 criteria for the disease and had a caps 5 total severity score of at least 28 and symptom duration of at least six months. caps 5 is considered the gold standard ptsd assessment scale. the patients were randomized to receive either a split dose of 80 mg or 120 mg mdma hydrochloride separated by 1.5 to 2 hours followed by 40 or 60 mg during three sessions of therapy or placebo with extended sessions of therapy. investigators assessed outcomes from baseline to the primary endpoint 18 weeks post baseline visit. patients treated with lykos’ mdma assisted therapy had better outcomes than those treated with placebo. the treatment resulted in a reduction in caps 5 total severity score from baseline to week 18 of  23.7 compared to a caps 5 total severity score change of  14.8 for the placebo during the same time period. the safety analysis showed that muscle tightness, nausea, decreased appetite and excessive sweating were all common adverse events in the treatment group, but they were mostly transient and mild or moderate in severity. similar to the mapp1 study, there were no new major safety issues reported and no reports of mdma abuse or dependence. despite these data, in june, the fda’s psychopharmacologic drugs advisory committee (pdac) voted 10 1 against recommending the treatment, saying the benefits of the drug do not outweigh the risks, even with a strict risk evaluation and mitigation strategy. the committee also voted 9 2 that lykos had not provided enough data showing the efficacy of the therapy in treating patients with ptsd. but rosenbaum said the negative advisory committee meeting might not necessarily mean the fda will opt against approving the treatment. “the one sidedness of the committee’s vote does represent a barrier to the fda approving the drug,” he said. “nonetheless, the relative lack of sophistication of the committee’s discussion and arguments will make it easier to override some of their concerns.” one of the main issues raised during the adcomm meeting was the way in which lykos conducted its clinical trials. among the concerns posed by the fda and adcomm committee members were selection bias, with a substantial number of participants having previously used mdma, and functional unblinding. “because a person can feel the drug, they are no longer blinded to the treatment condition,” said dan karlin, chief medical officer of mindmed, which is also developing psychedelic therapies. “that unblinding may lead to the change. we think that is overblown because [in] essentially all psychiatric drug trials, functional unblinding happens.” rosenbaum agreed that functional unblinding during its clinical trials is the biggest impediment for lykos. however, during the adcomm, the fda expressed a desire to find a suitable solution to this issue, which many companies developing new psychiatric drugs are also grappling with. rosenbaum suggested the functional unblinding issue could be solved by using blinded, remote ratings, robust effect sizes, plausible mechanisms of action, the weight of all open and controlled trials and human experience, and safety or credible risk mitigation strategies. another issue is that it is difficult for the fda to disentangle the effect of the drug and the effect of the psychotherapy, karlin said. while this concern is not uncommon for potential psychiatric therapies, it is especially pronounced in this class of drugs, he added. the majority of existing studies have shown that investigational mdma is better when it’s accompanied by psychotherapy, karlin noted. “what mdma doesn’t do is help on its own,” he said. “so, while mdma induces an acute change in people, it doesn’t seem to lead to lasting change without psychotherapy. so, really, it is the combination of the two.” on the safety front, the pdac raised questions regarding potential cardiovascular issues and hepatoxicity related to administration of the therapy. the fda did not require data regarding cardiovascular and liver toxicity risks, and lykos did not include such information in its filings. in a press release following the adcomm, lykos stated, “we will continue to work with the fda to characterize the data and/or collect new data to address these potential risks, if required. as we stated during the pdac meeting, we are confident that these can be safely addressed in a post marketing environment.” © 1985   2025 biospace.com. all rights reserved.

supported by the fallout from the f.d.a.’s rejection of mdma assisted treatment for ptsd worries researchers and experts who fear other psychedelic drugs in the pipeline could be jeopardized. by andrew jacobs and rachel nuwer a green beret who had served several combat tours fatally shot himself in a cybertruck that exploded outside a trump hotel on new year’s day. by dave philipps en una clínica cerca de tijuana, méxico, algunos pacientes de estados unidos han hallado alivio duradero de los problemas de salud mental con los que habían luchado desde sus días de combate. by dave philipps and mark abramson mandates in the annual appropriations act, passed on wednesday, call for the pentagon to track and mitigate risks to troops’ brains from firing their own weapons. by dave philipps people are turning to psilocybin, ketamine and other treatments for palliative care. by andrew jacobs unable to find effective treatments at home, veterans with brain injury symptoms are going abroad for psychedelics like ibogaine that are illegal in the u.s. by dave philipps and mark abramson a confidential navy program is studying whether intense fighter jet operations can cause devastating brain injuries in flight crews. by dave philipps the town of southampton, an affluent long island enclave, violated housing laws by rejecting the project, which would have helped veterans and disabled people, the suit says. by mihir zaveri the agency said there was insufficient data to allow the use of a treatment for ptsd that involves the drug known as ecstasy. by andrew jacobs the f.d.a. is poised to rule on the therapeutic use of the club drug ecstasy, a potential watershed moment in the nascent field of psychedelic medicine. by andrew jacobs

linkedin and 3rd parties use essential and non essential cookies to provide, secure, analyze and improve our services, and to show you relevant ads (including professional and job ads) on and off linkedin. learn more in our cookie policy. select accept to consent or reject to decline non essential cookies for this use. you can update your choices at any time in your settings. agree & join linkedin by clicking continue to join or sign in, you agree to linkedin’s user agreement, privacy policy, and cookie policy. bioethicist and scientist at camh “an independent group of experts expressed concerns that the data from clinical trials did not outweigh risks for treatment of post traumatic stress disorder.” https://lnkd.in/gnmtsgyc to view or add a comment, sign in 6 followers explore the various medication options for treating schizoaffective disorder. learn how antipsychotics, mood stabilizers, and antidepressants can help manage symptoms effectively. reach out for expert advice. #statenislandny #psychiatricservices #mentalhealth #schizoaffectivedisorder #medicationmanagement to view or add a comment, sign in 2023 otsuka elite winner. award winning, high performance sales leader   cultivates productive partnerships with customers  integrates technical information and market trend data into increased sales more than 13 million people in the u.s. are affected by post traumatic stress disorder (ptsd). ptsd may affect mental, physical, social, and/or the spiritual well being of a person. today, we are pleased to announce, in collaboration with lundbeck, the submission of a supplemental new drug application (snda) for u.s. fda review of brexpiprazole as a combination therapy with sertraline for the treatment of ptsd in adults. we will not rest until mental illnesses and brain diseases are approached with the same priority and urgency as our physical health. learn more here: https://lnkd.in/e7wqbnsf #defylimitation to view or add a comment, sign in director, long term care | 3x president’s club winner | leader & mentor | ltc expert | patient centric advocate more than 13 million people in the u.s. are affected by post traumatic stress disorder (ptsd). ptsd may affect mental, physical, social, and/or the spiritual well being of a person. today, we are pleased to announce, in collaboration with lundbeck, the submission of a supplemental new drug application (snda) for u.s. fda review of brexpiprazole as a combination therapy with sertraline for the treatment of ptsd in adults. we will not rest until mental illnesses and brain diseases are approached with the same priority and urgency as our physical health. learn more here: https://lnkd.in/euapj6qj #defylimitation to view or add a comment, sign in it business partner more than 13 million people in the u.s. are affected by post traumatic stress disorder (ptsd). ptsd may affect mental, physical, social, and/or the spiritual well being of a person. today, we are pleased to announce, in collaboration with lundbeck, the submission of a supplemental new drug application (snda) for u.s. fda review of brexpiprazole as a combination therapy with sertraline for the treatment of ptsd in adults. we will not rest until mental illnesses and brain diseases are approached with the same priority and urgency as our physical health. learn more here: https://lnkd.in/edcucbjy #defylimitation to view or add a comment, sign in salesforce solution architect/delivery lead more than 13 million people in the u.s. are affected by post traumatic stress disorder (ptsd). ptsd may affect mental, physical, social, and/or the spiritual well being of a person. today, we are pleased to announce, in collaboration with lundbeck, the submission of a supplemental new drug application (snda) for u.s. fda review of brexpiprazole as a combination therapy with sertraline for the treatment of ptsd in adults. we will not rest until mental illnesses and brain diseases are approached with the same priority and urgency as our physical health. learn more here: https://lnkd.in/ed3d s2x #defylimitation to view or add a comment, sign in 2,207 followers what are the different diagnostic criteria & treatment options for gad vs. panic disorder? a brief clinical summary on anxiety and panic disorders from the pcmed project, our sister site for primary care https://lnkd.in/gseptsge #mentalhealth #primarycare #anxiety #panicdisorder to view or add a comment, sign in 3,605 followers in this randomized controlled trial involving health care workers during the covid 19 pandemic, playing tetris after recalling an intrusive memory of a traumatic event reduced the number of intrusive traumatic memories that participants were experiencing. the study recruited 144 health care workers who had experienced a traumatic event at work, resulting in intrusive thoughts related to the event. participants were then randomly assigned to an intervention group or a control group. once at the beginning of the study, participants in the intervention group visualized something that reminded them of their traumatic memory and then played tetris for 20 minutes. after 5 weeks, the median frequency of intrusive memories was 80% lower in the tetris group compared to a control group. the tetris group also reported lower ptsd symptoms, with this benefit still present when participants were followed up with 6 months later. tetris may help reduce ptsd symptoms via a phenomenon called memory reconsolidation. in essence, by visually recalling traumatic triggers and then partially “distracting” the brain with a visual spatial task like tetris, the neural pathways that encode a traumatic memory are weakened, helping prevent intrusive memories in the future. learn more: https://lnkd.in/gn5nzwze #examined #tetris #trauma #mentalhealth to view or add a comment, sign in student at sheridan college katamine infusion therapy for ptsd disorder the use of ketamine infusion therapy might be beneficial. according to research, ketamine has also few adverse effects and can treat depression, anxiety, and other ptsd related disorders. continue reading to find out more about ketamine therapy, its background, and the advantages and disadvantages of ketamine infusion therapy for ptsd patients. read more: https://lnkd.in/drqeyfd9 to view or add a comment, sign in a new study published in the prestigious jama network open, has linked tonsillectomy with stress disorders. researchers mined sweden’s national health database and found 83,957 individuals who had their tonsils removed since 1981. these people were 43% more likely to develop stress related disorders over the next 30 years, including a 55% higher likelihood of developing ptsd. interestingly, those individuals who had had their tonsils removed in childhood were also significantly more likely to be hospitalized for an infectious disease over the next 30 years. it is possible that immunological changes that happen when tonsils are removed are responsible for increased susceptibility to stress in later life. this is interesting for sure. it should also add another important consideration when thinking about whether our kids should undergo tonsillectomy. the medical gains are truly modest and the negative outcomes could be significant. tag someone who needs to hear this! #tonsillectomy #stressdisorders #research #ptsd #stress #health to view or add a comment, sign in 5,890 followers canada’s largest inpatient treatment program for individuals experiencing anorexia nervosa, bulimia nervosa or other specified feeding or eating disorder (osfed) has been enhanced and relaunched. this program is designed to address the increasing complexity of the needs of individuals living with eating disorders. explore some unique facts on eating disorders here. 👇 ⭐ fact: 90% of individuals who attended homewood health centre's eating disorder program were below the clinical threshold for an eating disorder at the end of the program. in addition, individuals displayed positive improvement rates for the #anxiety scale, #depression severity index, self care index, change in care needs, depression and functioning, relationships, self harm, emotional lability, psychosis, and substance use. to find more on the program, click here: https://ow.ly/w0ce50tr2m9 #eatingdisorderrecovery #programrelaunch to view or add a comment, sign in 1,201 followers create your free account or sign in to continue your search or by clicking continue to join or sign in, you agree to linkedin’s user agreement, privacy policy, and cookie policy. new to linkedin? join now or new to linkedin? join now by clicking continue to join or sign in, you agree to linkedin’s user agreement, privacy policy, and cookie policy. linkedin never miss a beat on the app don’t have the app? get it in the microsoft store.

an official website of the united states government official websites use .gov a .gov website belongs to an official government organization in the united states. secure .gov websites use https a lock ( lock locked padlock icon ) or https:// means you've safely connected to the .gov website. share sensitive information only on official, secure websites. primary site navigation logged in as: corresponding author. received 2021 feb 5; accepted 2021 apr 2; issue date 2021. open access this article is licensed under a creative commons attribution 4.0 international license, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the creative commons license, and indicate if changes were made. the images or other third party material in this article are included in the article’s creative commons license, unless indicated otherwise in a credit line to the material. if material is not included in the article’s creative commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. to view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. post traumatic stress disorder (ptsd) presents a major public health problem for which currently available treatments are modestly effective. we report the findings of a randomized, double blind, placebo controlled, multi site phase 3 clinical trial (nct03537014) to test the efficacy and safety of 3,4 methylenedioxymethamphetamine (mdma) assisted therapy for the treatment of patients with severe ptsd, including those with common comorbidities such as dissociation, depression, a history of alcohol and substance use disorders, and childhood trauma. after psychiatric medication washout, participants (n = 90) were randomized 1:1 to receive manualized therapy with mdma or with placebo, combined with three preparatory and nine integrative therapy sessions. ptsd symptoms, measured with the clinician administered ptsd scale for dsm 5 (caps 5, the primary endpoint), and functional impairment, measured with the sheehan disability scale (sds, the secondary endpoint) were assessed at baseline and at 2 months after the last experimental session. adverse events and suicidality were tracked throughout the study. mdma was found to induce significant and robust attenuation in caps 5 score compared with placebo (p < 0.0001, d = 0.91) and to significantly decrease the sds total score (p = 0.0116, d = 0.43). the mean change in caps 5 scores in participants completing treatment was −24.4 (s.d. 11.6) in the mdma group and −13.9 (s.d. 11.5) in the placebo group. mdma did not induce adverse events of abuse potential, suicidality or qt prolongation. these data indicate that, compared with manualized therapy with inactive placebo, mdma assisted therapy is highly efficacious in individuals with severe ptsd, and treatment is safe and well tolerated, even in those with comorbidities. we conclude that mdma assisted therapy represents a potential breakthrough treatment that merits expedited clinical evaluation. subject terms: drug development, phase iii trials results from a phase 3, double blind, randomized, placebo controlled trial demonstrate that mdma assisted therapy is safe and effective in treating severe post traumatic stress disorder. ptsd is a common and debilitating condition with immeasurable social and economic costs that affects the lives of hundreds of millions of people annually. there are a number of environmental and biological risk factors that contribute to the development and maintenance of ptsd1, and poor ptsd treatment outcomes are associated with several comorbid conditions that include childhood trauma2, alcohol and substance use disorders3, depression4, suicidal ideation5 and dissociation6. it is therefore imperative to identify a therapeutic that is beneficial in those individuals with the comorbidities that typically confer treatment resistance. the selective serotonin reuptake inhibitors (ssris) sertraline and paroxetine are food and drug administration (fda) approved first line therapeutics for the treatment of ptsd. however, an estimated 40 60% of patients do not respond to these compounds7. likewise, although evidenced based trauma focused psychotherapies such as prolonged exposure and cognitive behavioral therapy are considered to be the gold standard treatments for ptsd8, many participants fail to respond or continue to have significant symptoms, and dropout rates are high9,10. novel cost effective therapeutics are therefore desperately needed11. the substituted amphetamine 3,4 methylenedioxymethamphetamine (mdma) induces serotonin release by binding primarily to presynaptic serotonin transporters12. mdma has been shown to enhance fear memory extinction, modulate fear memory reconsolidation (possibly through an oxytocin dependent mechanism), and bolster social behavior in animal models13,14. pooled analysis of six phase 2 trials of mdma assisted therapy for ptsd have now shown promising safety and efficacy findings15. here, we assess the efficacy and safety of mdma assisted therapy in individuals with severe ptsd. participants were given three doses of mdma or placebo in a controlled clinical environment and in the presence of a trained therapy team. primary and secondary outcome measures (caps 5 and sds, respectively) were assessed by a centralized pool of blinded, independent diagnostic assessors. mdma assisted therapy for ptsd was granted an fda breakthrough therapy designation, and the protocol and statistical analysis plan (sap) were developed in conjunction with the fda16. participants were recruited from 7 november 2018 to 26 may 2020, with the last participant visit conducted on 21 august 2020. a total of 345 participants were assessed for eligibility, 131 were enrolled, 91 were confirmed for randomization (united states, n = 77; canada, n = 9; israel, n = 5), and 46 were randomized to mdma and 44 to placebo (fig. 1). a, procedure timeline. following the screening procedures and medication taper, participants attended a total of three preparatory sessions, three experimental sessions, nine integration sessions and four endpoint assessments (t1 4) over 18 weeks, concluding with a final study termination visit. ir, independent rater; t, timepoint of endpoint assessment; t1, baseline; t2, after the first experimental session; t3, after the second experimental session; t4, 18 weeks after baseline. b, consort diagram indicating participant numbers and disposition through the course of the trial. study arms were not significantly different in terms of race, ethnicity, sex, age, dissociative subtype, disability or caps 5 score (table 1). the mean duration of ptsd diagnosis was 14.8 (s.d. 11.6) years and 13.2 (s.d. 11.4) years in the mdma and placebo groups, respectively. of note, six participants in the mdma group and 13 participants in the placebo group had the dissociative subtype according to caps 5 score. demographics and baseline characteristics bmi, body mass index; cbt, cognitive behavioral therapy; emdr, eye movement desensitization and reprocessing therapy. atwo participants included in the assigned female at birth mdma group identified their gender as non binary. bmedications were tapered down and washed out prior to baseline assessments and the first experimental session, in accordance with the protocol. clifetime accounts for all suicidal ideation and behavior prior to the study. serious ideation is defined as a score of 4 or 5 in the suicidal ideation category. mdma significantly attenuated ptsd symptomology, as shown by the change in caps 5 total severity score from baseline to 18 weeks after baseline. mixed model repeated measure (mmrm) analysis of the de jure estimand (that is, the effects of the drug if taken as directed) showed a significant difference in treatment arms (n = 89 (mdma n = 46), p < 0.0001, between group difference = 11.9, 95% confidence interval (ci) = 6.3 17.4, d.f. = 71) (fig. 2a). mmrm sensitivity analysis of the de facto estimand (that is, the effects of the drug if taken as assigned, regardless of adherence) showed a significant difference in treatment arms (n = 90, p < 0.0001, d.f. = 72). a, change in caps 5 total severity score from t1 to t4 (p < 0.0001, d = 0.91, n = 89 (mdma n = 46)), as a measure of the primary outcome. primary analysis was completed using least square means from an mmrm model. b, change in sds total score from t1 to t4 (p = 0.0116, d = 0.43, n = 89 (mdma n = 46)), as a measure of the secondary outcome. primary analysis was completed using least square means from an mmrm model. c, change in bdi ii score from t1 to study termination (t = −3.11, p = 0.0026, n = 81 (mdma n = 42)), as a measure of the exploratory outcome. data are presented as mean and s.e.m. the mean change in caps 5 scores from baseline to 18 weeks after baseline in the completers (per protocol set) was −24.4 (s.d. 11.6) (n = 42) in the mdma assisted therapy group compared with −13.9 (s.d. 11.5) (n = 37) in the placebo with therapy group. the effect size of the mdma assisted therapy treatment compared with placebo with therapy was d = 0.91 (95% ci = 0.44 1.37, pooled s.d. = 11.55) in the de jure estimand and d = 0.97 (95% ci = 0.51 1.42) in the de facto estimand. when the within group treatment effect (which included the effect of the supportive therapy that was administered in both arms) was compared between the mdma and placebo groups, the effect size was 2.1 (95% ci = −5.6 to 1.4) in the mdma group and 1.2 (95% ci = −4.9 to 2.5) in the placebo group. over the same period, mdma significantly reduced clinician rated functional impairment as assessed with the sds. mmrm analysis of the de jure estimand showed a significant difference in treatment arms (n = 89 (mdma n = 46), p = 0.0116, d.f. = 71, effect size = 0.43, 95% ci = −0.01 to 0.88, pooled s.d. = 2.53) (fig. 2b). the mean change in sds scores from baseline to 18 weeks after baseline in the completers was −3.1 (s.d. 2.6) (n = 42) in the mdma assisted therapy group and −2.0 (s.d. 2.4) (n = 37) in the placebo with therapy group. mdma was equally effective in participants with comorbidities that are often associated with treatment resistance. participants with the dissociative subtype of ptsd who received mdma assisted therapy had significant symptom reduction on the caps 5 (mean mdma δ = −30.8 (s.d. 9.0), mean placebo δ = −12.8 (s.d. 12.8)), and this was similar to that in their counterparts with non dissociative ptsd (mean mdma δ = −23.6 (s.d. 11.7), mean placebo δ = −14.3 (s.d. 11.2)). the benefit of mdma therapy was not modulated by history of alcohol use disorder, history of substance use disorder, overnight stay or severe childhood trauma. results were consistent across all 15 study sites with no effect by study site (p = 0.1003). in mmrm analysis there was no obvious impact of ssri history on effectiveness of mdma (supplementary table 2). mdma therapy was effective in an exploratory endpoint analysis of the reduction of depression symptoms (using the beck depression inventory ii (bdi ii)) from baseline to study termination of the de jure estimand (mean mdma δ = −19.7 (s.d. 14.0), n = 42; mean placebo δ = −10.8 (s.d. 11.3), n = 39; t = −3.11, p = 0.0026, d.f. = 79, effect size = 0.67, 95% ci = 0.22 1.12) (fig. 2c). clinically significant improvement (a decrease of ≥10 points on the caps 5), loss of diagnosis (specific diagnostic measure on the caps 5), and remission (loss of diagnosis and a total caps 5 score ≤ 11) were each tracked. at the primary study endpoint (18 weeks after baseline), 28 of 42 (67%) of the participants in the mdma group no longer met the diagnostic criteria for ptsd, compared with 12 of 37 (32%) of those in the placebo group after three sessions. additionally, 14 of 42 participants in the mdma group (33%) and 2 of 37 participants in the placebo group (5%) met the criteria for remission after three sessions (fig. 3). responders (clinically significant improvement, defined as a ≥10 point decrease on caps 5), loss of diagnosis (specific diagnostic measure on caps 5), and remission (loss of diagnosis and a total caps 5 score of ≤11) were tracked in both groups. non response is defined as a <10 point decrease on caps 5. withdrawal is defined as a post randomization early termination. treatment emergent adverse events (teaes, adverse events that occurred during the treatment period from the first experimental session to the last integration session) that were more prevalent in the mdma study arm were typically transient, mild to moderate in severity, and included muscle tightness, decreased appetite, nausea, hyperhidrosis and feeling cold (supplementary table 3). importantly, no increase in adverse events related to suicidality was observed in the mdma group. a transient increase in vital signs (systolic and diastolic blood pressure and heart rate) was observed in the mdma group (supplementary table 4). two participants in the mdma group had a transient increase in body temperature to 38.1 °c: one had an increase after the second mdma session, and one had an increase after the second and third mdma sessions. two participants, both randomized to the placebo group, reported three serious adverse events (saes) during the trial. one participant in the placebo group reported two saes of suicidal behavior during the trial, and another participant in the placebo group reported one sae of suicidal ideation that led to self hospitalization. five participants in the placebo group and three participants in the mdma group reported adverse events of special interest (aesis) of suicidal ideation, suicidal behavior or self harm in the context of suicidal ideation. one participant in the placebo group reported two cardiovascular aesis in which underlying cardiac etiology could not be ruled out (table 2). one participant randomized to the mdma group chose to discontinue participation due to being triggered by the caps 5 assessments and to an adverse event of depressed mood following an experimental session; this participant met the criterion as a non responder, which was defined as having a less than 10 point decrease in caps 5 score. mdma sessions were not otherwise followed by a lowering of mood. participants with treatment emergent saes and aesis the number of participants experiencing one or more saes or aesis relating to suicidality, cardiovascular symptoms that could indicate qt prolongation, and abuse potential following the first experimental session. suicidality was tracked throughout the study using the columbia suicide severity rating scale (c ssrs) at each study visit. more than 90% of participants reported suicidal ideation in their lifetime, and 17 of 46 participants (37%) in the mdma group and 14 of 44 participants (32%) in the placebo group reported suicidal ideation at baseline. although the number of participants who reported suicidal ideation varied throughout the visits, prevalence never exceeded baseline and was not exacerbated in the mdma group. serious suicidal ideation (a score of 4 or 5 on the c ssrs) was minimal during the study and occurred almost entirely in the placebo arm (fig. 4). c ssrs ideation scores range from 0 (no ideation) to 5. a c ssrs ideation score of 4 or 5 is termed ‘serious ideation’. the number of participants endorsing any positive ideation (>0) is shown by the colored bars and noted in the table below the graph. the number of participants endorsing serious ideation is given in parentheses in the table. here, we demonstrate that three doses of mdma given in conjunction with manualized therapy over the course of 18 weeks results in a significant and robust attenuation of ptsd symptoms and functional impairment as assessed using the caps 5 and sds, respectively. mdma also significantly mitigated depressive symptoms as assessed using the bdi ii. of note, mdma did not increase the occurrence of suicidality during the study. these data illustrate the potential benefit of mdma assisted therapy for ptsd over the fda approved first line pharmacotherapies sertraline and paroxetine, which have both exhibited smaller effect sizes in pivotal studies16. previous comparison of change in caps score between sertraline and placebo showed effect sizes of 0.31 and 0.37 (ref. 16). similarly, comparison of change in caps score between paroxetine and placebo showed effect sizes of 0.56, 0.45 and 0.09 (ref. 16). by contrast, the effect size of 0.91 demonstrated in this study between mdma assisted therapy and placebo with therapy was larger than that for any other previously identified ptsd pharmacotherapy16 18. to directly assess superiority, a head to head comparison of mdma assisted therapy with ssris for ptsd would be needed. although the present study tested the effects of mdma using a model in which both treatment groups received supportive therapy, participants who received mdma and supportive therapy (d = 2.1) had greater improvement in ptsd change scores compared with those who received placebo with supportive therapy (d = 1.2), suggesting that mdma enhanced the effects of supportive therapy. in clinical practice, both mdma and supportive therapy will be components of this ptsd treatment. previous research on mdma for ptsd has suggested that those with a recent history of ssri treatment may not respond as robustly to mdma18. given that 65.5% of participants in the current trial have a lifetime history of ssri use, it is difficult to separate the ramifications of long term ssri treatment from the effects of treatment resistance. however, there was no obvious effect of previous ssri use on therapeutic efficacy in this trial. similarly, although years of ptsd diagnosis or age of onset may affect treatment efficacy, no obvious relationship was seen here between duration or onset of ptsd diagnosis and treatment efficacy. serotonin and the serotonin transporter are of particular importance in the generation, consolidation, retrieval and reconsolidation of fear memories19,20. reduced serotonin transporter levels (which result in greater amounts of extracellular serotonin) have been shown to predict propensity to develop ptsd21, increase fear and anxiety related behaviors22, and induce greater amygdalar blood oxygenation level dependent (bold) activity in response to fearful images23. there is extensive serotonergic innervation of the amygdala, and amygdalar serotonin levels have been shown to increase following exposure to stressful and fear inducing stimuli24. mdma enhances the extinction of fear memories in mice through increased expression of brain derived neurotrophic factor in the amygdala, and human neuroimaging studies have demonstrated that mdma is associated with attenuated amygdalar bold activity during presentation of negative emotional stimuli25. together these data suggest that mdma may exert its therapeutic effects through a well conserved mechanism of amygdalar serotonergic function that regulates fear based behaviors and contributes to the maintenance of ptsd. perhaps by reopening an oxytocin dependent critical period of neuroplasticity that typically closes after adolescence15, mdma may facilitate the processing and release of particularly intractable, potentially developmental, fear related memories. it is intriguing to speculate that the pharmacological properties of mdma, when combined with therapy, may produce a ‘window of tolerance,’ in which participants are able to revisit and process traumatic content without becoming overwhelmed or encumbered by hyperarousal and dissociative symptoms26. mdma assisted therapy may facilitate recall of negative or threatening memories with greater self compassion27 and less ptsd related shame and anger28. additionally, the acute prosocial and interpersonal effects of mdma25,29 may support the quality of the therapeutic alliance, a potentially important factor relating to ptsd treatment adherence30 and outcome31. indeed, clinicians have suggested that “mdma may catalyze therapeutic processing by allowing patients to stay emotionally engaged while revisiting traumatic experiences without becoming overwhelmed“32. given that ptsd is a strong predictor of disability in both veteran and community populations33, it is promising to note that the robust reduction in ptsd and depressive symptoms identified here is complemented by a significant improvement in sds score (for example, work and/or school, social and family functioning). approximately 4.7 million us veterans report a service related disability34, costing the us government approximately $73 billion per year35. identification of a ptsd treatment that could improve social and family functioning and ameliorate impairment across a broad range of environmental contexts could provide major medical cost savings, in addition to improving the quality of life for veterans and others affected by this disorder. ptsd is a particularly persistent and incapacitating condition when expressed in conjunction with other disorders of mood and affect. in the present study, perhaps most compelling are the data indicating efficacy in participants with chronic and severe ptsd, and the associated comorbidities including childhood trauma, depression, suicidality, history of alcohol and substance use disorders, and dissociation, because these groups are all typically considered treatment resistant2 6. given that more than 80% of those assigned a ptsd diagnosis have at least one comorbid disorder3, the identification of a therapy that is effective in those with complicated ptsd and dual diagnoses could greatly improve ptsd treatment. additional studies should therefore be conducted to evaluate the safety and efficacy of mdma assisted therapy for ptsd in those with specific comorbidities. although recent research suggests that dissociative subtype ptsd is difficult to treat36, participants with the dissociative subtype who received mdma assisted therapy had significant symptom reduction that was at least similar to that of their counterparts with non dissociative ptsd. given that this covariate was significant, it warrants further study. furthermore, given that other treatments for ptsd are not consistently effective for those with the dissociative subtype, these data, if replicated, would indicate an important novel therapeutic niche for mdma assisted therapy for typically hard to treat populations. importantly, there were no major safety issues reported in the mdma arm of this study. although abuse potential, cardiovascular risk and suicidality were recorded as aesis, mdma was not shown to induce or potentiate any of these conditions. in addition, although there was often a transient increase in blood pressure during mdma sessions, this was expected based on phase 2 data and previous studies in healthy volunteers37. these data suggest that mdma has an equivalent, if not better, safety profile compared with that of first line ssris for the treatment of ptsd, which are known to carry a low risk of qt interval prolongation38. there are several limitations to the current trial. first, due to the coronavirus disease 2019 (covid 19) pandemic, the participant population is smaller than originally planned. however, given the power noted in this study, it is unlikely that population size was an impediment. second, the population is relatively homogeneous and lacks racial and ethnic diversity, which should be addressed in future trials. third, this report describes the findings of a short term pre specified primary outcome, 2 months after the last experimental session and 5 weeks since the final integrative therapy session; long term follow up data from this controlled trial will be collected to assess durability of treatment. fourth, safety data were by necessity collected by site therapists, perhaps limiting the blinding of the data. to eliminate this effect on the primary and secondary outcome measures, all efficacy data were collected by blinded, independent raters. last, given the subjective effects of mdma, the blinding of participants was also challenging and possibly led to expectation effects14. however, although blinding was not formally assessed during the study, when participants were contacted to be informed of their treatment assignment at the time of study unblinding it became apparent that at least 10% had inaccurately guessed their treatment arm. although anecdotal, at least 7 of 44 participants in the placebo group (15.9%) inaccurately believed that they had received mdma, and at least 2 of 46 participants in the mdma group (4.3%) inaccurately believed that they had received placebo. we may soon be confronted with the potentially enormous economic and social repercussions of ptsd, exacerbated by the covid 19 pandemic. overwhelmingly high rates of psychological and mental health impairment could be with us for years to come and are likely to impart a considerable emotional and economic burden. novel ptsd therapeutics are desperately needed, especially for those for whom comorbidities confer treatment resistance. in summary, mdma assisted therapy induces rapid onset of treatment efficacy, even in those with severe ptsd, and in those with associated comorbidities including dissociative ptsd, depression, history of alcohol and substance use disorders, and childhood trauma. not only is mdma assisted therapy efficacious in individuals with severe ptsd, but it may also provide improved patient safety. compared with current first line pharmacological and behavioral therapies, mdma assisted therapy has the potential to dramatically transform treatment for ptsd and should be expeditiously evaluated for clinical use. this was a randomized double blind study designed to compare the efficacy of mdma assisted therapy with that of placebo with therapy. fifteen study sites, consisting of 11 in the united states, two in canada and two in israel, included both institutional sites and private clinics. ethics approval was obtained from copernicus group independent review board, western institutional review board, university of british columbia providence healthcare research ethics board, and the helsinki committees of be’er ya’akov ness ziona mental health center and chaim sheba medical center. this clinical study was conducted in accordance with the principles of the declaration of helsinki. the public study protocol is available at http://maps.org/mapp1. the therapist manual is available at http://maps.org/treatment manual. participants were recruited through print and internet advertisements, referrals from treatment providers, and by word of mouth. participants were required to initiate contact with the study sites themselves, even if recommended by a provider. after providing written informed consent, participants were screened for eligibility. the criteria for inclusion consisted of meeting the diagnostic and statistical manual of mental disorders, fifth edition (dsm 5) criteria for current ptsd with a symptom duration of ≥6 months at screening (as assessed with the mini international neuropsychiatric interview (mini) for dsm 5), and a caps 5 total severity score of ≥35 at baseline. exclusion criteria consisted of primary psychotic disorder, bipolar i disorder, dissociative identity disorder, eating disorders with active purging, major depressive disorder with psychotic features, personality disorders, current alcohol and substance use disorders, pregnancy or lactation, and any medical condition that could make receiving a sympathomimetic drug harmful due to increased blood pressure and heart rate, including uncontrolled hypertension, history of arrhythmia, or marked baseline prolongation of qt and/or qtc interval. participants with other mild, stable, chronic medical problems (for example, type 2 diabetes mellitus or well controlled hypertension) were eligible for enrollment if the site physician, clinical investigator and medical monitor agreed that the condition would not increase the risk associated with mdma administration. participants were required to comply with lifestyle modifications, including a medically supervised discontinuation of psychiatric medications for a minimum of five half lives plus one additional week before the baseline assessments (see the study protocol for inclusion and exclusion criteria). the study protocol was amended on three occasions during study enrollment: first, to add clarity to eligibility criteria related to comorbid medical conditions; second, to add terms of suicidal ideation and behavior as aesis, as requested by the fda; and third, to increase the frequency of suicidality assessments following experimental sessions, as requested by the fda, and to add an option for some telemedicine visits following the covid 19 pandemic. given that the study was at full enrollment (n = 105) when covid 19 shut down in person interactions at most of the study sites, the fda and sponsor concluded that a reduced sample size of 90 participants, instead of the planned 100, would maintain sufficient statistical power to meet study objectives and would avoid covid 19 delays of experimental sessions, which might confound the assessment of treatment effects. the study drug was manufactured in accordance with current good manufacturing practice (cgmp) standards by onyx scientific and compounded by sharp clinical services. assays for chemistry, manufacturing and controls were completed in accordance with the cgmp and international council for harmonisation of technical requirements for pharmaceuticals for human use (ich) standards, and reported to the fda, health canada and the israel ministry of health. participants were randomized in a blinded fashion and were allocated 1:1 to either the mdma assisted therapy group or the placebo with therapy group. randomization was stratified by site and occurred following enrollment confirmation (after preparatory visits). randomization was managed via an interactive web randomization system itclinical iwrs, version 11.0.1 (itclinical, lda) based on a centralized randomization schedule developed by an independent third party vendor to maintain blinding. participants, site staff and the sponsor were blinded to participant group assignment until after the database was locked. an inactive placebo with therapy was utilized as the comparator to isolate the efficacy of the mdma itself. although low dose mdma improved blinding in phase 2 studies, it led to decreased effectiveness compared with an inactive placebo in a ptsd population, making it easier to detect a difference between the active and comparator groups15. the use of inactive placebo also allows for uncontaminated comparison of safety data between groups. therefore, an inactive placebo was determined in partnership with the fda as a more conservative statistical comparison, and the study utilized observer blinded efficacy assessments to minimize bias in efficacy measurements. an observer blind and centralized independent rater pool was used to administer the primary and secondary outcome measures, that is, the caps 5 and the sds for functional impairment, the latter of which was adapted to limit missing item level data as per the fda requirements and included use of the three item mean as the total score and imputation of work related impairment as the maximum score, if caused by ptsd. the independent rater measurements were conducted at baseline and following each experimental session via live video interviews. independent raters did not repeatedly see the same participant and the independent rater pool was blinded to the complete study design, visit number, treatment assignment, and all data collected by the therapy team after baseline, with the exception of safety data related to suicidality. participants were instructed to withhold their opinion on treatment group assignment from independent raters and to refrain from sharing details regarding the study design and their number of completed visits. to ensure that all site and sponsor staff were shielded from study outcome measures, primary and secondary outcome measures were collected from the blinded independent rater pool and stored in a dedicated database that was separate from the blinded, clinical database. following an initial phone screening, participants provided written informed consent and underwent further screening assessments for eligibility. these included the ptsd checklist for dsm 5 (pcl 5), the mini for dsm 5, the structured clinical interview for dsm 5 screening personality questionnaire and structured clinical interview for dsm 5 personality disorders (scid 5 spq and  pd), the lifetime c ssrs, medical history, and pre study medications. study staff contacted outside providers, ordered medical records, and conducted a physical examination, laboratory testing (including pregnancy and drug tests), electrocardiogram, and 1 min rhythm strip. eligible participants were enrolled in the study and began psychiatric medication taper (table 1) if needed, and collection of adverse events. anticipated effects of mdma, such as euphoria, stimulation and feelings of closeness39, were intentionally not solicited as adverse events to avoid biasing the collection of adverse event data. participant medication taper was variable, lasting from 0 d (no taper needed) to 103 d. clinical data were electronically captured using medrio edc versions r40 r40.7. in accordance with fda guidance, we paid special attention to a subset of adverse events, termed aesis, relating to cardiac function that could be indicative of qt interval prolongation or cardiac arrhythmias, abuse liability, and suicidal ideation and behavior. all adverse events that included signs or symptoms potentially associated with a cardiovascular event such as palpitations or dizziness were further evaluated for reporting as a cardiovascular adverse event. to assess signs of mdma abuse potential, any adverse event terms such as ‘behavioral addiction’, ‘drug abuser’, ‘substance abuser’, ‘dependence’, ‘intentional product misuse’, ‘overdose’ (accidental, intentional or prescribed) or ‘drug diversion’ were collected and coded as aesis. suicidal ideation that was judged as serious or severe by the investigator, serious ideation defined as a c ssrs suicidal ideation score of a 4 or 5, self harm in the context of any suicidal ideation, and any suicide attempts were reported as aesis. enrolled participants underwent three 90 min preparatory sessions of therapy with a two person therapist team in preparation for experimental sessions (fig. 1). the preparatory sessions focused on establishing therapeutic alliance and trust, and also provided guidance on how to respond to the memories and feelings that could arise during treatment. participants who failed to meet all eligibility criteria were withdrawn during this preparatory period. baseline caps 5 assessment (to confirm ptsd diagnosis and total severity score of ≥ 35 for randomization) was performed by the independent rater pool after completion of two preparatory sessions and any necessary psychiatric medication taper to establish baseline symptom severity following removal of psychiatric medications. at the end of the preparatory period, participants were assessed for final eligibility and enrollment was confirmed prior to randomization (fig. 1). the treatment period consisted of three 8 h experimental sessions of either mdma assisted therapy or therapy with inactive placebo control, spaced ~4 weeks apart. following a 10 h fast, experimental sessions began with a qualitative urine drug screen, pregnancy screen if applicable, and c ssrs, as well as measurement of baseline blood pressure, body temperature and heart rate immediately before the initial drug dose. any positive findings on the urine drug screen that could not be attributed to pre approved concomitant medications were reviewed by the medical monitor to assess compliance with ongoing eligibility criteria and for possible aesis. experimental sessions were conducted following a circadian rhythm adjusted dosing schedule for a morning (~10:00 hours) initial dose. in each experimental session the participants received a single divided dose of 80 180 mg mdma or placebo. in the first experimental session, an initial dose of 80 mg was followed by a supplemental half dose of 40 mg 1.5 2.5 h after the first dose. in the second and third experimental sessions, an initial dose of 120 mg was followed by a supplemental half dose of 60 mg. if tolerability issues emerged with the initial dose or if participants declined, the protocol permitted the supplemental dose and/or dose escalation to be withheld. there were no instances in which the supplemental dose was withheld due to tolerability issues. six participants chose either not to take the supplemental dose (n = 3, 1 mdma) or not to escalate to the 120 mg dose (n = 3, 2 mdma) in a total of six experimental sessions (2.3% of the total sessions across the study). blood pressure, body temperature and heart rate were measured before the supplemental dose was given14. manualized therapy was conducted in accordance with the mdma assisted therapy treatment manual (http://maps.org/treatment manual). therapy was inner directed and designed to invite inquiry and to facilitate therapeutic effect by providing support for approaching difficult material in a manner that would not interfere with the participant’s spontaneous experience. every therapist held a master’s degree or above, and the protocol requirement was that one person per therapy team was licensed to provide psychotherapy in accordance with state and local requirements. therapists were additionally required to take part in the sponsor’s five part training process, which consisted of an online course (15 h), a training course (5 d), experiential learning (3 d), role playing (1 d), and supervision (52 h). blood pressure, body temperature and heart rate were measured at the end of each experimental session prior to discharging the participant. each experimental session was followed by three 90 min integration sessions that were spaced ~1 week apart to allow the participant to understand and incorporate their experience. the first integration session always occurred on the morning after the experimental session, and the remaining two integration sessions occurred over the following 3 4 weeks (fig. 1). independent raters conducted caps 5 and sds assessments ~3 weeks after each of the first two experimental sessions. the primary outcome assessment was conducted ~8 weeks after the third experimental session (18 weeks after the baseline assessment), in which the independent raters collected the final caps 5 and sds assessments. twenty per cent of independent rater assessments were randomly selected and reviewed for fidelity. lead independent raters evaluated the fidelity of all assessments related to enrollment failures as well as an additional 20% of remaining baseline caps 5 assessments. diagnostic concordance between the raters had a cohen’s kappa coefficient of 0.94, and reliability analysis of the caps 5 total severity scores showed a spearman correlation coefficient of 0.98 (p < 0.0001), demonstrating high inter rater reliability between the independent raters. the independent raters were all mental health professionals with graduate level training in psychology, social work or counseling, at least 1 year of experience working with trauma exposed populations, and had previous experience administering structured assessments. cases of non compliance, protocol deviations, loss to follow up, and other reasons for participant dropout were assessed for the presence of aesis. there were two major protocol deviations (defined as the eligibility criteria not being met by the randomized participants during the course of the study). in the first protocol deviation a participant was not compliant with drug use lifestyle modifications on study, and in the second protocol deviation a participant disclosed cannabis use at study entry but abstained for the duration of the study. there was one dosing error in which a participant in the placebo group received 80 mg placebo as an initial dose and 100 mg as a supplemental dose (n = 1). additionally, 14 participants (10 of whom were in the mdma arm) requested further integrative visits, as permitted by the protocol. the primary objective of this trial was to evaluate the efficacy and safety of mdma assisted therapy for ptsd compared with placebo with therapy, based on comparison of caps 5 total severity score at baseline with that at 18 weeks after baseline. the caps 5 is a semi structured interview that assesses the index history of dsm 5 defined traumatic event exposure, including the most distressing event, to produce a diagnostic score (presence versus absence) and a ptsd total severity score. the caps 5 rates intrusion symptoms (intrusive thoughts or memories), avoidance, cognitive and mood symptoms, arousal and reactivity symptoms, duration and degree of distress, and dissociation. the caps 5 is scored on a scale from 0 to 80, with moderate ptsd defined from a rationally derived severity range of 23 34 (ref. 40), and severe ptsd as ≥35. the secondary objective of this trial was to evaluate the efficacy of mdma assisted therapy for ptsd compared with placebo with therapy in clinician rated functional impairment, as measured by the mean change in sds total scores from baseline to 18 weeks after baseline. exploratory outcome measures included the bdi ii, the alcohol use disorders identification test (audit), the drug use disorders identification test (dudit) and the adverse childhood experiences (ace) questionnaire. participants agreed to be recontacted for potential enrollment in a long term follow up study, which will include follow up measures to assess the durability of the treatment. these data will be published at a later date. statistical power calculations for the initial sample size were made by fitting an mmrm of caps 4 data (converted to the caps 5 scale and pooled from the phase 2 studies) to obtain variance and covariance parameter estimates. using the estimated effect size and variance and covariance parameters, the sample size was calculated to achieve a power of 90% at an alpha of 0.049. the intent to treat (itt) set consisted of 91 randomized participants, however, one participant declined dosing on the morning of the session and provided no additional data, and therefore it was not possible to complete this analysis. participants were randomized in a blinded fashion with 1:1 allocation as described in the section on randomization, masking and bias minimization above. the modified intent to treat (mitt) set consisted of 90 randomized participants who had completed at least one blinded experimental session and at least one post treatment assessment. the mitt set consisted of 46 participants randomized to the mdma group and 44 participants randomized to the placebo group, with identical therapy. the per protocol set (completers) consisted of all participants who completed three experimental sessions and assessments (mdma, n = 42; placebo, n = 37) (fig. 1). the sap was guided by the ich e9 (r1) guidelines, which describe the use of estimands and sensitivity analyses to measure the effects of the drug if taken as directed (de jure, assessment of efficacy), and the effects of the drug if taken as assigned, regardless of adherence (de facto, assessment of effectiveness). the sap was developed in accordance with fda requirements and was approved by the european medicines agency to meet the requirements for future marketing applications. the primary and secondary efficacy analyses therefore utilized a de jure estimand of the mitt set for assessing treatment efficacy from the caps 5 and sds data while on the study drug. the de jure dataset did not include outcome measurements taken after treatment discontinuation in the analysis of treatment efficacy. missing data were not imputed. one participant in the placebo group completed only the baseline assessment, and discontinued intervention but provided caps data at the t4 timepoint, ~18 weeks after baseline. given that no endpoint assessment was collected prior to treatment discontinuation, this participant is excluded from the de jure estimand (leaving n = 89) but is included in the de facto estimand sensitivity analysis (for a total of n = 90). two additional caps data points at the t4 timepoint, ~18 weeks after baseline, from two participants in the placebo group who provided these data following discontinuation of treatment, were not included in the de jure estimand (supplementary table 1). the de facto estimand assessed the impact of these missing data points in the mitt set. that is, the caps measures at the t4 timepoint, ~18 weeks after baseline for the three placebo participants who discontinued treatment but provided off treatment outcome assessments were included in a sensitivity analysis, which determined that inclusion of these measures in the model did not significantly alter the results. the primary and secondary efficacy analyses were carried out using an mmrm that included all outcome data from baseline and the first, second and third experimental sessions. the efficacy of treatment was tested by comparing the change from baseline to the third experimental session in caps 5 and sds scores between treatment groups in two sided tests. the fixed effects were treatment (mdma or placebo), baseline caps score, dissociative subtype and investigational site, with random effect specified as study participant. a hierarchical testing strategy was used to control for type i error, such that the hypothesis for the key secondary endpoint (sds) would be tested only if the statistical test for the primary efficacy comparison rejected the null hypothesis. an analysis of covariance (ancova) to test the effects of study participation before versus after the covid 19 pandemic declaration by the world health organization indicated a non significant interaction and therefore was not included in the primary outcome model (supplementary table 2). the primary outcome analysis was replicated independently by one blinded programmer and one unblinded programmer. an independent data monitoring committee monitored adverse events for safety and conducted one administrative interim analysis, after completion of enrollment and of 60% of primary endpoints to examine the adequacy of the sample size. the data monitoring committee recommended that no additional participants should be added, based on conditional power calculations supporting 90% statistical power, but in keeping with the sap did not provide the sponsor with any information on the conditional power or effect size. the alpha level was set to 0.05, and 2% of the alpha (0.001) was spent on the interim analysis and 98% (0.0499) was left for the final analysis. statistics for the primary and secondary efficacy comparisons (caps and sds) are reported as p values from the results of the mmrm analysis. in exploratory analyses, additional baseline covariates of age, gender, ethnicity, prior use of ssris, depression as measured by the bdi ii, adverse childhood experiences, and alcohol and substance use disorders were assessed in the model, with the threshold of significance set at p < 0.05 (supplementary table 1). bdi ii score was also assessed as an exploratory efficacy outcome measure with a paired, two tailed t test. results are reported as mean (s.d.) throughout the text. between group effect size was calculated with cohen’s d, and 95% cis are reported. sas version 9.4 (sas institute) was used for analyses. the safety analysis included all participants who were given at least one dose of the study drug or placebo. the primary safety analysis evaluated teaes as a participant level analysis. an association with mdma was determined based on the relative incidence of teaes with at least a twofold difference between the mdma and placebo groups. further information on research design is available in the nature research reporting summary linked to this article. any methods, additional references, nature research reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at 10.1038/s41591 021 01336 3. supplementary tables 1 4. the authors thank all of the participants who screened for and participated in this challenging research study, and acknowledge the oversight of the principal investigators, t. nachsoni (be’er ya’akov, israel) and n. puri (university of british columbia, canada). the authors thank the study coordinators s. sadler, k. brown, c. marsicano, m. wimsatt, b. bendixsen, d. bissell, s. serice, m. gaffigan, c. miller, r. bacigalupi, b. deyo, a. baltes, t. baron, l. owens, s. robison, d. gumpel, c. battistelli, a. samkavitz, k. blommaert, a. menier, d. katz, e. pushkarski, n. somech and m. bar haim for their work at their respective study sites. the authors are especially grateful to charleston study coordinator s. sadler, who passed away prior to the end of this study after a decade of work on this and several prior multidisciplinary association for psychedelic studies (maps) clinical trials. the authors also acknowledge the following study therapists for their skillful treatment of study participants: s. braswell, w. reynolds, c. reusche, e. passow, s. gael giron, d. may, j. beachy, k. cooper, a. schnaitter, c. hancock, c. heacock, b. balliett, e. siegal, n. brüss, v. kraft, a. booth, j. mccowan, s. taylor, m. skellie, z. hippel, m. alavi, c. stauffer, d. mcdivitt, a. rosati, k. peoples, e. sola, a. penn, s.e. sienknecht, g. herzberg, h. schwartz, v. gold, j. andries, c. thomas, s. ross, j. guss, j.h. duane, e. nielson, k. o’donnell, w. hall, e. nielson, p. lister, e. horowitz, a. belser, j. guss, j. silverman, s. walker, j. hopper, m. alpert, f. guerriero, a. st. goar, e. call, c. jackson, j. simundic, h. rubensohn, k. lutz, s. adams, t. nachsoni, n. halberstadt, d. dogon, k.t. and i. siemion. the authors thank the site physicians, nurses, research assistants, volunteers, night attendants, physical examiners and all site staff who contributed their time and effort to the study. the authors acknowledge the following select members of the maps pbc internal team who organized the study: m. brown and g. fortier, for their work in clinical trial management; a. nary, p. perl, e. shainer, a. pace and s. ndukwe for careful monitoring of study data; a. schwind, p. llorach, m. leighton, d. iszak, s. ramey wright and e. gworek for tireless support of the study administration; s. garcia velazquez for her review of participant safety data; j. lindgren for coordination of irb submissions; e. heimler for dedicated effort in coordinating the independent rater pool; a. wang, j. lin and a. garcia for overseeing the adherence rating and supervision programs; s. scheld for supporting therapist and supervisor training and the development of the code of ethics; j. poncini, c. shelley, m. tromba and a. o’keefe for developing the technology and procedures to collect and manage session recordings with security and care; h. clouting, b. melton and k. cohn for coordinating drug supply; a. feduccia for her work on the phase 2 program that paved the way for this phase 3 trial; and c. hennigan for the creation of the clinical databases. the authors also thank g. more for statistical programming, the teams of independent raters for their attention to detail and care for participants during outcome assessments, and the adherence raters for their close evaluation of the therapeutic delivery. no compensation was provided beyond normal compensation of employment. this clinical trial was sponsored by maps, a 501(c)(3) non profit organization. maps provided the mdma and fully funded this study from private donations. maps public benefit corporation (maps pbc), wholly owned by maps, was the trial organizer. maps pbc provided the study design and the monitoring of study data; analysis, management and interpretation of data; reviewed and approved the paper; and submitted the paper for publication. the funder had no role in the collection of data or in conducting the study. j.m.m., b.y. k., s.h. and a.c. had full access to all of the data in the study and take responsibility for the integrity of the data and for the accuracy of the data analysis. r.d., m.m., b.y. k., a.e., r.m., c.h. and a.l. conceived and designed the study. m.o.g., b.p., w.g., s.q., c.p., i.g., r.w., j.m.m., s.s., g.w., b.v.d.k., c.m., y.g., s.s.k., e.h., s.a., m.b., r.a., y.w., c.n., r.b. and k.t. collected the data. s.c., m.m., a.m., m.o.g., b.p., s.k., k.p. g. and k.t. carried out supervision and training. c.h., r.m., a.l., b.y. k., a.e. and a.d.b. carried out sponsor oversight of data collection. j.m.m., a.c. and b.y. k. drafted the paper. j.m.m., b.y. k., a.d.b., m.b., a.l., c.h., s.k., k.p. g., a.c., s.h., r.d., j.b.w., b.v.d.k., m.o.g., w.g., c.p., i.g., c.n., m.m., s.c., b.p., g.w., s.s.k., e.h., a.e., j.d.w., s.s., y.g., s.a., r.w. and c.m. critically revised the paper for important intellectual content. s.h., j.b.w., b.y. k., a.c., s.k. and a.d.b. carried out statistical analysis and interpretation of data. r.d. obtained funding. the data that support the findings of this study are available from the sponsor (maps). however, restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. data are, however, available from the authors upon reasonable request and with the permission of maps at http://maps.org/datause. all requests for raw and analyzed data are promptly reviewed by the sponsor delegate and trial organizer, maps pbc, to verify if the request is subject to any confidentiality obligations. patient related data not included in the paper were generated as part of clinical trials and may be subject to patient confidentiality. any data that can be shared will be released via a data use agreement. commercially available software (sas version 9.4, sas institute) was used for analyses, in keeping with the sap. the authors declare the following financial competing interests: a.e., r.m., c.h., a.d.b., s.c., a.c. and j.b.w. received salary support for full time employment with maps pbc for this study and other work; a.l., b.y. k. and r.d. received salary support for full time employment with maps for this study and other work; m.m., a.m., m.o.g., b.p. and k.t. received support as contractors from maps pbc for training and supervision of research psychotherapists for this study and other work; s.k., k.p. g. and s.h. received support as contractors of maps pbc for their contributions to this study and other work; and study investigators and researchers, j.m.m., m.b., m.o.g., w.g., c.p., i.g., c.n., b.p., s.q., g.w., s.s.k., b.v.d.k., k.t., r.a., r.w., s.s., j.d.w., c.m., y.g., e.h., s.a., y.w. and r.b., received funding from maps pbc during the conduct of the study for this study as well as other studies. the following authors disclose receipt of personal fees or grants from companies in the field, but unrelated to the present work: m.b. (heffter research institute, turnbull family foundation, b. more, mind medicine, fournier family foundation, bill linton, george sarlo foundation, riverstyx foundation, dr. bronners family foundation, and national institutes of health), c.p. (fluence and mindbloom), j.d.w. (filament ventures and silo pharmaceuticals), and j.m.m. and a.c. (usona institute). the following authors disclose non financial relationships with organizations in the field: m.m. and a.m. serve on the scientific advisory board for awaken life sciences, c.p. co founded nautilus sanctuary and nautilus psychiatric services, s.s. serves on the advisory board for maya health, and i.g. serves on the scientific advisory board of journey clinical and co founded fluence. peer review information nature medicine thanks philip cowen, kirsty james and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. jerome staal was the primary editor on this article and managed its editorial process and peer review in collaboration with the rest of the editorial team. publisher’s note springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. the online version contains supplementary material available at 10.1038/s41591 021 01336 3. this section collects any data citations, data availability statements, or supplementary materials included in this article. supplementary tables 1 4. the data that support the findings of this study are available from the sponsor (maps). however, restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. data are, however, available from the authors upon reasonable request and with the permission of maps at http://maps.org/datause. all requests for raw and analyzed data are promptly reviewed by the sponsor delegate and trial organizer, maps pbc, to verify if the request is subject to any confidentiality obligations. patient related data not included in the paper were generated as part of clinical trials and may be subject to patient confidentiality. any data that can be shared will be released via a data use agreement. commercially available software (sas version 9.4, sas institute) was used for analyses, in keeping with the sap. articles from nature medicine are provided here courtesy of nature publishing group connect with nlm national library of medicine 8600 rockville pike bethesda, md 20894

an official website of the united states government official websites use .gov a .gov website belongs to an official government organization in the united states. secure .gov websites use https a lock ( lock locked padlock icon ) or https:// means you've safely connected to the .gov website. share sensitive information only on official, secure websites. primary site navigation logged in as: corresponding author. received 2023 jun 2; accepted 2023 aug 24; issue date 2023. open access this article is licensed under a creative commons attribution 4.0 international license, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the creative commons licence, and indicate if changes were made. the images or other third party material in this article are included in the article’s creative commons licence, unless indicated otherwise in a credit line to the material. if material is not included in the article’s creative commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. to view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. this multi site, randomized, double blind, confirmatory phase 3 study evaluated the efficacy and safety of 3,4 methylenedioxymethamphetamine assisted therapy (mdma at) versus placebo with identical therapy in participants with moderate to severe post traumatic stress disorder (ptsd). changes in clinician administered ptsd scale for dsm 5 (caps 5) total severity score (primary endpoint) and sheehan disability scale (sds) functional impairment score (key secondary endpoint) were assessed by blinded independent assessors. participants were randomized to mdma at (n = 53) or placebo with therapy (n = 51). overall, 26.9% (28/104) of participants had moderate ptsd, and 73.1% (76/104) of participants had severe ptsd. participants were ethnoracially diverse: 28 of 104 (26.9%) identified as hispanic/latino, and 35 of 104 (33.7%) identified as other than white. least squares (ls) mean change in caps 5 score (95% confidence interval (ci)) was −23.7 (−26.94, −20.44) for mdma at versus −14.8 (−18.28, −11.28) for placebo with therapy (p < 0.001, d = 0.7). ls mean change in sds score (95% ci) was −3.3 (−4.03, −2.60) for mdma at versus −2.1 (−2.89, −1.33) for placebo with therapy (p = 0.03, d = 0.4). seven participants had a severe treatment emergent adverse event (teae) (mdma at, n = 5 (9.4%); placebo with therapy, n = 2 (3.9%)). there were no deaths or serious teaes. these data suggest that mdma at reduced ptsd symptoms and functional impairment in a diverse population with moderate to severe ptsd and was generally well tolerated. clinicaltrials.gov identifier: nct04077437. subject terms: drug development, trauma results from the phase 3 placebo controlled mapp2 trial show that mdma assisted therapy reduces post traumatic stress disorder (ptsd) symptoms and functional impairment in a diverse population with moderate to severe ptsd. post traumatic stress disorder (ptsd) is a serious neuropsychiatric condition affecting approximately 5% of the us population each year1. managing ptsd is particularly complicated in individuals experiencing the dissociative subtype of ptsd, recurrent exposure to trauma and comorbidities, such as mood disorders and alcohol and substance use disorders2 4. together, these factors are associated with symptom exacerbation, treatment resistance and treatment discontinuation3,5. trauma focused psychotherapies are the gold standard treatment for ptsd. however, many individuals have persisting symptomology, and dropout rates are high6 8. although the selective serotonin reuptake inhibitors (ssris) sertraline and paroxetine are fda approved for treating ptsd, 35 47% of individuals do not respond to treatment9. more effective, therapeutic interventions are needed to address the immense individual, societal and economic burdens of ptsd10,11. mounting evidence supports substituted phenethylamine 3,4 methylenedioxymethamphetamine assisted therapy (mdma at) as a treatment for ptsd12,13. mdma, an entactogen that promotes monoamine reuptake inhibition and release (primarily by inducing conformational change of pre synaptic transporters14 17), effectively modulates fear memory reconsolidation, enhances fear extinction and promotes openness and prosocial behavior18 22. several phase 2 trials indicated that mdma at has an acceptable risk benefit profile in individuals with ptsd13. a pivotal phase 3 study (mapp1) showed that mdma at was generally well tolerated and met the trial’s primary and secondary endpoints of reduced ptsd symptom severity and decreased functional impairment12. due to disparities in trauma exposure, gender diverse and transgender individuals, ethnoracial minorities, first responders, military personnel, veterans and victims of chronic sexual abuse have a disproportionately higher risk of developing ptsd2,23 28. however, these diverse populations are historically underrepresented in clinical trials29. here we report the results of mapp2, the second, confirmatory phase 3 study that extends the findings of mapp1 (refs. 12,30) in an ethnoracially diverse population with moderate to severe ptsd (supplementary table 1). participants were recruited from 21 august 2020 to 18 may 2022 (last participant visit on 2 november 2022). overall, 324 individuals were screened, and 121 were enrolled. of these, 17 individuals did not meet enrollment confirmation after initiation of preparation therapy, and 104 were confirmed for randomization: 53 were assigned to mdma at and 51 to placebo with therapy (fig. 1). ninety four participants completed the study, and nine discontinued (n = 1 mdma at; n = 8 placebo with therapy) (fig. 1 and supplementary table 3). consort diagram, indicating participant numbers and disposition throughout the course of the trial. endpoint assessments (t1, t2, t3 and t4) of caps 5 and sds were conducted after each experimental session. athe number of individuals after an initial phone screening who gave informed consent. bother reasons for exclusion could include withdrawal of consent, adverse event or death, discontinuation of treatment by investigator, lack of therapeutic rapport and illness or lost to follow up. cone participant in the placebo with therapy group completed the study but had missing item level data on the final caps 5 assessment, and the final assessment was not included in the analysis of the de jure estimand. ae, adverse event; itt, intention to treat; mitt, modified intention to treat; t, time of endpoint assessment; t1, baseline; t2, after experimental session 1; t3, after experimental session 2; t4, 6 8 weeks after experimental session 3 (18 weeks after baseline). baseline characteristics were generally similar between groups (table 1). in total, 74 of 104 (71.2%) participants were assigned female sex at birth, with a higher proportion in the placebo with therapy group (42/51, 82.4%) than the mdma at group (32/53, 60.4%). participants were ethnically and racially diverse: 35 of 104 (33.7%) participants identified their race as other than white, and 28 of 104 (26.9%) identified their ethnicity as hispanic/latino. the mean (s.d.) duration of ptsd was 16.2 (13.3) years. the mean (s.d.) clinician administered ptsd scale for dsm 5 (caps 5) score at baseline was 39.0 (6.6) and was similar between groups. overall, 28 of 104 (26.9%) and 76 of 104 (73.1%) participants had moderate and severe ptsd, respectively; the dissociative subtype was present in 24 of 104 (23.1%) participants. demographics and clinical characteristics of participants at baseline amedications were tapered and washed out before baseline assessments and the first experimental session, in accordance with the protocol. ace, adverse childhood experience; bmi, body mass index. mdma at significantly attenuated ptsd symptomology versus placebo with therapy, as measured by a reduction in caps 5 total severity score from baseline to 18 weeks. mixed models for repeated measures (mmrm) analysis of the de jure estimand showed a least squares (ls) mean (95% confidence interval (ci)) change of −23.7 (−26.94, −20.44) for mdma at versus −14.8 (−18.28, −11.28) for placebo with therapy (treatment difference: −8.9 (−13.70, −4.12), p < 0.001; fig. 2a). the cohen’s d effect size of mdma at versus placebo with therapy was d = 0.7; the within group effect sizes were d = 1.95 for mdma at and d = 1.25 for placebo with therapy. mmrm analysis of the de facto estimand revealed an ls mean change (95% ci) in caps 5 scores of −23.7 (−26.97, −20.47) for the mdma at group versus −14.8 (−18.24, −11.33) for the placebo with therapy group (p < 0.001). a, ls mean change (±s.e.m.) in caps 5 total severity score from baseline to after session 3 (primary outcome) for placebo with therapy (n = 50) versus mdma at (n = 53, p < 0.001, cohen’s d = 0.7). b, ls mean change (±s.e.m.) in sds total score from baseline to after session 3 (key secondary outcome) for placebo with therapy (n = 50) versus mdma at (n = 53, p = 0.03, cohen’s d = 0.4). source data mdma at significantly mitigated clinician rated functional impairment, as measured by a reduction in the sheehan disability scale (sds) from baseline. mmrm analysis of the de jure estimand revealed that the ls mean change (95% ci) in sds total scores was −3.3 (−4.03, −2.60) with mdma at versus −2.1 (−2.89, −1.33) with placebo with therapy (treatment difference: −1.20 (−2.26, −0.14); p = 0.03, d = 0.4; fig. 2b). improvements were observed across all domains, including family life, social life and work life (supplementary table 4). in the mdma at group, 45 of 52 (86.5%) participants were responders with a clinically meaningful improvement at 18 weeks after baseline, defined as a ≥10 point reduction in caps 5 total severity score, versus 29 of 42 (69.0%) in the placebo with therapy group (fig. 3). by study end, 37 of 52 (71.2%) participants in the mdma at group no longer met dsm 5 criteria for ptsd versus 20 of 42 (47.6%) participants in the placebo with therapy group. furthermore, 24 of 52 (46.2%) participants in the mdma at group and nine of 42 (21.4%) participants in the placebo with therapy group met remission criteria (fig. 3). the net number of participants needed to treat for each responder analysis group was as follows: responder, six; non responder, six; loss of diagnosis, four; remission, four. a ≥10 point reduction in caps 5 total severity score was considered to be clinically meaningful. responders (≥10 point reduction from baseline), loss of diagnosis (≥10 point reduction from baseline and no longer meeting ptsd diagnostic criteria) and remission (loss of diagnosis and caps 5 total severity score of 11 or less) were tracked in both groups as a percentage of participants. non responders were defined as any caps 5 total severity score change <10 point reduction from baseline. source data covariate analyses demonstrated similar responses to treatment regardless of disease severity, risk of hazardous alcohol or substance use disorder, severe adverse childhood experiences or dissociative subtype ptsd. the only measured exploratory covariate with a significant interaction with treatment was lifetime history of ssri use, which was associated with improved efficacy of mdma at (p = 0.02; supplementary table 5). covariates significantly impacting the main effect were sex assigned at birth and baseline beck depression inventory (bdi) ii score; female sex assigned at birth and baseline bdi ii score ≥23 were both associated with improved outcomes irrespective of treatment assignment (p < 0.05). a blinding survey conducted at study termination showed that 33 of 44 (75.0%) participants in the placebo with therapy group were certain or thought they received placebo, whereas nine of 44 (20.5%) participants inaccurately thought that they received mdma, and two of 44 (4.5%) participants could not tell. in the mdma at group, 49 of 52 (94.2%) participants were certain or thought that they received mdma; one of 52 (1.9%) participants inaccurately thought that they received placebo; and two of 52 (3.8%) participants could not tell (supplementary table 6). when asked for the reason for their belief in treatment assignment, most participants in the mdma at group reported attributing their response on the blinding survey to experiencing positive mental or emotional effect (45/52 (86.5%)) and positive physical effect (29/52 (55.8%)), whereas most of the participants in the placebo with therapy group reported experiencing no effect (28/44 (63.6%)). most participants (102/104, 98.1%) experienced at least one treatment emergent adverse event (teae) during the study (table 2); seven experienced a severe teae (mdma at, n = 5 (9.4%); placebo with therapy, n = 2 (3.9%)). none had a serious teae. two participants (3.9%) in the placebo with therapy group discontinued treatment due to teaes. frequently reported teaes (occurring with incidence >10% and at least twice the prevalence in the mdma at group versus the placebo with therapy group) included muscle tightness, nausea, decreased appetite and hyperhidrosis (table 2). these were mostly transient and of mild or moderate severity. at least one treatment emergent adverse event of special interest (teaesi) occurred in six of 53 (11.3%) participants in the mdma at group and three of 51 (5.9%) participants in the placebo with therapy group (table 2). no teaesis of mdma abuse, misuse, physical dependence or diversion were reported. adverse events occurring during treatment athe most common teaes occurring with incidence >10% and at least twice the prevalence in the mdma at group versus the placebo with therapy group. eight participants (mdma at, n = 7; placebo with therapy, n = 1) experienced cardiac teaes, which included palpitations (mdma at, n = 5 (9.4%); placebo with therapy, n = 1 (2.0%)) and tachycardia (mdma at, n = 2 (3.8%)); all were mild. nine participants (mdma at, n = 7; placebo with therapy, n = 2) experienced vascular teaes; all were mild, except for one participant in the mdma at group who had a history of hypertension, who was not taking anti hypertensive medications and who experienced a teae of moderate hypertension (supplementary table 7). five participants had cardiac teaesis: four participants in the mdma at group and one participant in the placebo with therapy group reported palpitations (supplementary table 7). participants in the mdma at group experienced temporary dose dependent increases in mean blood pressure (bp) and pulse during experimental sessions compared to the placebo with therapy group (supplementary table 8). transient increases in heart rate and bp were expected and were observed during experimental sessions in a dose dependent manner. greater fluctuations in bp were seen during experimental sessions 2 and 3 in the participants treated with mdma, most likely due to the higher doses of mdma administered. these transient elevations did not require clinical intervention, including among the subset of participants with well controlled hypertension. because the current dosing regimen involves administering a single, split drug dose under observation, for a limited number of times, each after a lengthy washout, cardiovascular risk is likely to have been sufficiently mitigated by the study procedures and screening measures. psychiatric teaes occurred at a similarly high frequency in both groups (mdma at, n = 44 (83.0%); placebo with therapy, n = 37 (72.5%)), with suicidal ideation, insomnia and anxiety reported most frequently. psychiatric teaes were mostly mild to moderate; three severe events occurred in the mdma at group (5.7%; n = 1 each: dissociation, flashback and grief reaction) and two in the placebo with therapy group (3.9%; n = 1 each: agitation and anxiety). no severe teaes of suicidal ideation or behavior were reported. two participants in the mdma at group had suicidality teaesis of suicidal ideation, one of whom engaged in non suicidal self injurious behavior. two participants in the placebo with therapy group had suicidality teaesis; one engaged in non suicidal self injurious behavior, and one had suicidal ideation and trichotillomania (supplementary table 9). more than 80% (87/104) of participants had a lifetime history of suicidal ideation; 13 of 53 (24.5%) in the mdma at group and 12 of 51 (23.5%) in the placebo with therapy group reported suicidal ideation during the final preparation session (v4). the number of participants reporting positive suicidal ideation varied throughout the study but collectively never exceeded baseline values in either group (supplementary fig. 2). three participants (two mdma at and one placebo with therapy) had treatment emergent active suicidal ideation with at least some intent to act (columbia suicide severity rating scale (c ssrs) score of 4 or 5), which was observed on five occasions (mdma at, three events; placebo with therapy, two events) (supplementary fig. 2). of these, one participant in the mdma at group with no suicidal ideation at baseline had the emergence of active suicidal ideation with at least some intent to act. in this confirmatory phase 3 study of participants with moderate to severe ptsd, mdma at significantly improved ptsd symptoms and functional impairment, as assessed by caps 5 and sds, respectively, compared to placebo with therapy over 18 weeks. notably, 45 of 52 (86.5%) participants treated with mdma at achieved a clinically meaningful benefit, and 37 of 52 (71.2%) participants no longer met criteria for ptsd by study end. in a historic first, to our knowledge, for psychedelic treatment studies, participants who identified as ethnically or racially diverse encompassed approximately half of the study sample. these findings confirm and extend the results observed in mapp1 (ref. 12), with general consistency across endpoints. given the diverse population and degree of participant complexity, the replication of efficacy is particularly notable. in our study, 26.9% (28/104) of participants expressed moderate ptsd, whereas, in mapp1, all participants expressed severe ptsd12. a substantial proportion of participants displayed comorbid features associated with high treatment resistance5, such as major depression, multiple sources of trauma (including childhood and combat trauma) and dissociative subtype ptsd. in keeping with mapp1, treatment was not significantly affected by disease severity, risk of hazardous alcohol or substance use disorder, severe adverse childhood experiences or dissociative subtype. furthermore, there was no observed site to site variability and no differential effect if participants stayed overnight after the experimental session. however, lifetime history of ssris, female sex assigned at birth and bdi ii score ≥23 at baseline were associated with positive impacts on outcomes and may warrant further study based on the exploratory nature of these analyses. mdma simultaneously induces prosocial feelings and softens responses to emotionally challenging and fearful stimuli19, potentially enhancing the ability of individuals with ptsd to benefit from psychotherapy by reducing sensations of fear, threat and negative emotionality18,19. the low dropout rate for mdma at has been replicated across seven studies, suggesting that mdma induces a true shift in participant engagement12,13. in contrast, a recent study comparing psychotherapies in veterans with ptsd reported dropout rates of 55.8% and 46.6% for prolonged exposure and cognitive processing therapy, respectively31. the mapp2 dropout rate was 1.9% (1/53) in the mdma at group and 15.7% (8/51) in the placebo with therapy group. the higher proportion of dropouts in the placebo with therapy group relative to mdma at could be attributed to participants receiving less effective treatment and to disappointment from ineffective therapeutic blinding, although blinding survey data showed that not all participants correctly identified the treatment that they received. consistent with mapp1, no new major safety issues were reported. common teaes were similar to previous studies and consistent with expected effects of mdma12,32. rates of cardiac teaes were low, and increases in bp and pulse were mild, transient and consistent with mdma’s sympathomimetic effects18,33,34. consistent with ptsd, suicidal ideation was observed in both groups. mdma did not appear to increase this risk, and no suicidal behavior was observed. c ssrs scores varied throughout the study but never exceeded baseline values for either group. notably, there were five total events of treatment emergent c ssrs scores of 4 or 5: three in the mdma at group and two in the placebo with therapy group. mapp2 enrolled participants with a history of suicidality but excluded those with a current, serious imminent suicide risk; thus, special attention to this vulnerable population is warranted in future studies. in alignment with mapp1 (ref. 12), there were no reports of problematic mdma abuse or dependence, including in participants with histories of, or current, alcohol and substance use disorders. however, it is important to note that participants with any substance use disorder other than cannabis or alcohol in the 12 months before enrollment were excluded from mapp2, as were participants with severe or moderate (in early remission) alcohol or cannabis use disorder. however, exploratory findings from the mapp1 phase 3 trial indicated that mdma at was actually associated with a significantly greater reduction in mean alcohol use disorder identification test change scores compared to placebo with therapy, suggesting that the effects of mdma at on hazardous alcohol use secondary to ptsd should be further studied35. long term data are also needed to assess the risk of mdma abuse or misuse after study participation. although the sample sizes of the mapp1 and mapp2 phase 3 studies had 90% statistical power and were developed with guidance from the fda to ensure adequate, rigorous testing of outcomes, these evaluations did not extend further than 2 months after therapy and were intended to support an acute treatment course. to support these studies, data from the ongoing follow up of participants from phase 2 and 3 studies (clinicaltrials.gov identifier: nct05066282) will be important for further assessment of the long term effectiveness of mdma at in participants with ptsd. it is of interest to note that pooled phase 2 analyses of participants with at least 12 months of follow up after their final mdma at session have shown that ls mean caps iv scores continue to improve between the final session and follow up32. several limitations may impact the integration of mdma at into clinical care, including the exclusion of participants with high suicide risk, comorbid personality disorders and underlying cardiovascular disease. observed effect sizes for mdma at (between group, d = 0.7; within subject, d = 1.95) were similar to mapp1 (ref. 12) (between group, d = 0.91; within subject, d = 2.1), and, although higher than those observed in ssri studies (ranging from 0.09 to 0.56 versus placebo for sertraline and paroxetine36), the superiority of mdma at over ssris cannot be assumed without a direct comparison. the complex relationship between ssri use/history and mdma at treatment efficacy was beyond the scope of the current statistical analysis plan and sample size but will be important to consider in future studies. in addition, further study of mdma with other forms of psychotherapy for ptsd should be explored. the notable effect seen in the placebo with therapy arm could suggest the standalone value of the manualized inner directed therapy that was developed for use with mdma. additional head to head studies will need to be conducted to evaluate whether this form of manualized therapy provides greater value in the treatment of ptsd than the current first line cognitive behavioral therapy and prolonged exposure therapy treatments37. although treatment expectancy, per se, was not measured in this study, prospective treatment expectancy would likely have been high in both study arms, with random assignment expected to distribute this equally between groups. although expectancy effects are a well known issue in psychiatric clinical trials and are intertwined with the observation of treatment benefit during a trial38, several observations support expectancy mitigation in the current study: (1) the groups did not separate after the first experimental session; (2) placebo with therapy dropouts did not uniformly occur after the first experimental session; and (3) blinding survey data (supplementary table 6) showed that not all participants correctly identified the treatment that they received. the therapists who participated in this study were required to complete the sponsor’s training program (see supplementary methods for further details). to ensure consistent clinical practice and to mitigate harm, it may be of benefit for prescribers to complete additional training and continuing education if mdma at is approved for use by a regulatory agency. this confirmatory phase 3 trial showed consistent benefits of mdma at in an ethnoracially diverse group of individuals with longstanding moderate to severe ptsd and numerous comorbidities. the dropout rate was low, and treatment was generally well tolerated. these findings represent the culmination of over two decades of research39, and, together with mapp1, indicate that further consideration of this treatment in individuals with moderate to severe ptsd is warranted. this multi site, randomized, double blind, placebo controlled study assessed the efficacy and safety of mdma at versus placebo with therapy in participants diagnosed with moderate or severe ptsd (nct04077437). thirteen study sites (11 in the united states and two in israel, both institutional and private) participated. the trial was conducted in accordance with the good clinical practice guidelines of the international council for harmonization and with the ethical principles of the declaration of helsinki. an independent data monitoring committee ensured that the study was conducted safely and had sufficient sample size. the review boards and institutions that approved the study protocol are listed in the supplementary methods. after written informed consent, participants were screened for eligibility. adults (≥18 years of age) meeting the full dsm 5 criteria for current ptsd per caps 5 assessment40,41 and a caps 5 total severity score ≥28 (moderate or higher severity) with symptom duration of ≥6 months were eligible for enrollment confirmation. during the preparation period that preceded the treatment period, participants were tapered off all psychiatric medications before baseline to avoid potential drug interactions and confounding efficacy (supplementary fig. 1). full inclusion and exclusion criteria are outlined in the supplementary methods. participants were randomized in a 1:1 allocation and in a blinded fashion to the mdma at and placebo with therapy groups, stratified by clinical site. randomization was managed via an interactive web randomization system (iwrs) (it clinical version 11.0.1) based on a centralized randomization schedule developed by an independent third party vendor to maintain blinding. a central pool of blinded independent assessors was used to mitigate the risk of functional unblinding42. assessors were trained and supervised by independent consultants with expertise in ptsd diagnostics and the caps 5 to ensure inter rater reliability and validity of assessments. supervision involved reviewing each assessor’s first two assessments as well as 20% of all assessments (chosen at random) throughout the study, with each review resulting in detailed feedback for the assessor. the independent assessors were blinded to the general study design, study visit, treatment assignment, number of treatments received and any safety data for the participant. participants were instructed to withhold their opinion on treatment group assignment and the number of completed visits from the independent assessors. each assessor conducted no more than one caps 5 assessment with each participant to reduce potential bias and expectancy effect from having conducted repeat caps 5s with a participant. assessors were also vetted before their onboarding to ensure that there were no conflicts of interest (such as other involvement within the multidisciplinary association for psychedelic studies (maps) organization or a bias toward mdma at), and assessors were instructed to not expose themselves to scholarly presentations and papers related to mdma at for ptsd to maintain their blinding to study design. to ensure that all site and sponsor staff were shielded from study outcomes, the blinded independent assessor pool collected and stored outcome measures in a dedicated database that was separate from the blinded clinical database. a blinding survey was conducted at study termination (visit 20) to assess if participants thought that they received mdma or placebo. trial procedures were consistent with mapp1 (ref. 12). enrolled participants underwent three 90 min preparation sessions with a two person therapy team, including at least one licensed therapist, and were then randomized 1:1 to receive mdma at or placebo with therapy for approximately 3 months. the treatment period consisted of three 8 h dosing sessions, in conjunction with therapy, spaced approximately 1 month apart. therapy was conducted by trained personnel in accordance with the maps mdma at treatment manual (https://maps.org/treatment manual) and trial protocol. during experimental sessions, and in keeping with the dosing in mapp1, participants received a split dose of 120 180 mg of mdma or placebo. for the first experimental session, the initial dose of 80 mg was followed by a supplemental half dose of 40 mg. in the second and third experimental sessions, the initial dose of 120 mg was followed by a supplemental half dose of 60 mg. the supplemental half dose was administered 1.5 2 h after the initial dose. participants in both treatment groups received identical therapy. the 120 mg (80 mg + 40 mg) split dose was selected for the first experimental session in phase 3 trials to allow patients to acclimate to the treatment regimen using a clinical titration approach based on clinician recommendations from a phase 2 trial in veterans and first responders13. during the second and third experimental sessions, doses were escalated to 180 mg (120 mg + 60 mg), as this was the most frequently studied efficacious dose in phase 2 trials. this dosing regimen also provides clinicians with the option of dose adjustments if needed. within the mdma at group, three participants did not undergo dose escalation in experimental sessions 2 and 3, and two participants experienced dose administration timing errors (supplementary table 2). each experimental session was followed by three 90 min integration sessions to support participants in processing and understanding their experience (supplementary fig. 1). full procedures, including details on therapy teams and training, are outlined in the supplementary methods. independent assessors conducted caps 5 and sds outcome assessments at baseline, after experimental sessions 1 and 2 and 6 8 weeks after experimental session 3 (18 weeks after baseline) via video interviews. primary and secondary objectives were mean change in caps 5 total severity and sds scores, respectively, for mdma at versus placebo with therapy from baseline to 18 weeks after baseline. exploratory outcome measurements included characterization of the treatment response and differences between the treatment groups by demographics and characteristics. responder analyses were based on categorical diagnostic assessment data and the caps 5 total severity score assessment. ptsd severity was defined using the caps 5 total severity score as follows: asymptomatic (0 10), mild (11 22), moderate (23 34), severe (35 46) and extreme (47+) (ref. 41). a ≥10 point reduction in caps 5 total severity score was considered to be clinically meaningful as agreed upon with the fda through a special protocol assessment. four responder categories were derived and compared at each post experimental session visit using caps 5 scores. these categories were: non responder (<10 point reduction from baseline), responder (≥10 point reduction from baseline), loss of diagnosis (≥10 point reduction from baseline and no longer meeting ptsd diagnostic criteria) and remission (caps 5 total severity score of 11 or less and no longer meeting ptsd diagnostic criteria). safety objectives included assessment of differences between groups in severity, incidence and frequency of teaes, serious teaes, teaesis, suicidal ideation and behavior and vital signs. teaes were defined as any adverse event that occurred during the treatment period from the first experimental session to the last integration session. the severity of teaes was determined by the site physician as mild (no limitation in normal daily activity), moderate (some limitation in normal daily activity) or severe (unable to perform normal daily activity). a serious teae was defined as any unforeseen medical event at any dose of the drug that resulted in death; was life threatening; required inpatient hospitalization; caused significant disability or incapacity; resulted in a congenital anomaly or birth defect; or required intervention to prevent permanent impairment or damage. serious teaes also included any event, based on medical judgement, that jeopardized the participant or may have required intervention to prevent one of the events listed previously. with the exception of serious adverse event reporting, relatedness to study drug was not assessed by investigators, to preserve blinding. in an effort to identify common adverse events that may be most related to mdma, teaes occurring with incidence >10% and at least twice the prevalence in the mdma at group versus the placebo with therapy group are reported. suicidality was tracked at each study visit using the c ssrs (see the supplementary methods for more information). sas version 9.4 (sas institute) was used for analyses. sample size was calculated to achieve a power of 90% at an alpha of 0.0499. efficacy was tested using an mmrm analysis comparing the change from baseline to 18 weeks after baseline in caps 5 and sds scores between treatment groups in two sided tests with alpha set at 0.0499. the alpha was adjusted to account for an administrative interim analysis for sample size re estimation conducted after all participants were enrolled and 60% of primary endpoint data had been collected. fixed effects were treatment, visit, treatment group by visit interaction and dissociative subtype; baseline caps 5 score was a covariate. primary and secondary efficacy analyses used a de jure (related to initially randomized treatment) estimand and a supportive de facto (treatment policy) estimand of the modified intention to treat population, which required exposure to mdma or placebo and at least one follow up caps 5 assessment, as in mapp1 (ref. 12). the de jure dataset included all available data, except for 12 (one mdma at and 11 placebo with therapy) outcome measurements taken after treatment discontinuation in analysis of treatment efficacy (supplementary table 3). missed observations were considered missing at random (mar), and choice of this assumption was tested with a tipping point analysis (supplementary methods). in additional exploratory analyses, 13 covariates were assessed in the model, with alpha set at 0.0499: age, sex (self reported), prior use of selective ssris, work disability, disease severity, ptsd duration, dissociative subtype, overnight site stay, site id, moderate depression (as measured by the bdi ii), severe adverse childhood experiences and moderate alcohol and substance use disorder risk (as measured by the drug use disorders identification test and the alcohol use disorders identification test). analyses of primary or secondary outcomes by gender were not planned a priori; some exploratory analyses included sex as a covariate (supplementary methods). safety analysis evaluated teaes at the participant level, including all participants who received mdma or placebo. causal association with mdma was determined based on relative incidence of teaes with at least a two fold difference between groups. in accordance with fda guidance, special attention was paid to a subset of adverse events, teaesis, relating to cardiac function, suicide risk and mdma abuse, misuse or diversion. teaesis involving cardiac function that could be indicative of qt prolongation or cardiac arrhythmias were collected, including torsade de pointes, sudden death, ventricular extrasystoles, ventricular tachycardia, ventricular fibrillation and flutter, non postural syncope and seizures. teaesis involving suicide risk included suicide, suicide attempts, self harm associated with suicidal ideation, suicide ideation assessed as a score of 4 or 5 on the c ssrs and suicidal ideation judged by the investigator to be serious/severe. teaesis involving terms of mdma abuse, misuse, drug diversion, dependence or overdose were also collected. further information on research design is available in the nature portfolio reporting summary linked to this article. any methods, additional references, nature portfolio reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at 10.1038/s41591 023 02565 4. consort checklist, mapp2 study collaborators, supplementary methods, supplementary figs. 1 and 2, supplementary tables 1 9 and supplementary references. statistical source data. statistical source data. the authors thank all of the participants and their support networks. see the supplementary information for acknowledgments concerning study collaborators, including all members of the mapp2 study collaborator group. this study was funded by multidisciplinary association for psychedelic studies (maps) with support from the steven and alexandra cohen foundation and organized by maps public benefit corporation (pbc). maps pbc was responsible for overseeing the collection, analysis and interpretation of the data. medical writing assistance was provided by j. carpenter and m. yochum of boldscience, funded by maps pbc. s.h., b.y. k., c.h. and a.d.b. contributed to data analysis; these authors and j.m.m. directly accessed and collectively verified the underlying data. all authors had full access to the trial data, contributed to the interpretation of the data and contributed to writing the manuscript. the authors attest to the accuracy and completeness of the reported data, accept responsibility to submit for publication and confirm that the trial conformed to the protocol and the statistical analysis plan (available via nature medicine). nature medicine thanks matthias liechti, alimu dayimu and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. primary handling editor: jerome staal, in collaboration with the nature medicine team. the data that support the findings of this study are available from the sponsor beginning 1 year after completion of the trial. however, restrictions apply to the availability of these data, which were used under license for the current study and so are not publicly available. data are, however, available from the authors upon reasonable request and with the permission of the sponsor. all requests for raw and analyzed data are promptly reviewed to verify if the request is subject to any confidentiality obligations. participant related data not included in the paper were generated as part of clinical trials and may be subject to participant confidentiality. any data that can be shared will be released via a data use agreement. proposals should be directed to https:/maps.org/datause. source data are provided with this paper. commercially available software (sas version 9.4 or higher, sas institute) was used for analyses, in keeping with the statistical analysis plan. j.m.m. has received research support from maps; grants/contracts from the veterans administration (merit award) and the fda (research award); has received royalties/licenses from ucla (for a patent licensed to ucsf for cell screening); has received payment/honoraria from stanford (for lecturing to undergraduate students) and johns hopkins (for presenting grand rounds); has a patent licensed to ucsf for cell screening; has been a reviewer for niaaa ctn; has been a member of ca doj rap; and has been a grant reviewer for the australian medical research council. m.o.g.: aguazul bluewater, inc has received research support from maps pbc and payments from cybin (training and consultation), from horizons conference and from naropa university. b.v.d.k. has received royalties from penguin random house (book, the body keeps the score) and guilford press (book, traumatic stress); has received consulting fees from meadows hospital (wickenburg, arizona); and has received payment/honoraria from pesi. b.v.d.k. is also the president of the trauma research foundation. s.s. has received grants/contracts from maps (research support) and mindmed (research support); has received royalties/licenses from academic press and norton publishing (professional books); has received honoraria from scripps, the integrative psychiatric institute and the institute of functional medicine (lectures and presentations); is member of the maya health advisory board; and previously served as ceo of the board of psychedelic medicine and therapies. m.b. has received grant support to his institution for the current study from maps pbc; has received grants/contracts to his institution from mend medicine, tilray canada and the heffter research institute; has been paid by ajna labs, journey colab and bright minds biosciences for advisory board participation; and has received drug to his institution from tilray canada for an nih funded trial. y.g. anticipates support from maps pbc for congress attendance in the future and has stock in mindmed. c.p. has received grants/contracts (research support) and consulting fees from maps pbc (training and supervision/consultation). c.r.n. has received grants/contracts fromm maps pbc (research studies); has received payment/honoraria from maps pbc and mindmed (training and educational events); has received meeting/travel support from maps pbc; and has received funding for contract work as an mdma assisted therapy trainer. s.q. has received grants/contract support for research from maps. b.b. has received support for the present study from new school research and the california center for psychedelic therapy; has received consulting fees from maps pbc (training and supervision/consultation); has received payment/honoraria from the integrative psychiatric institute, the california association of marriage and family therapists, the los angeles county psychological society and the palm springs art museum (lectures/speaking events); has received support for meetings/travel from maps pbc; and is a trainer representative for the maps pbc commercial advisory committee and supervisor and coordinator of the zendo project (psychedelic harm reduction). s.h. is an employee of maps pbc. m.m. has received support for the present research from maps pbc (independent contractor) and is a member of the awakn life sciences scientific advisory board; has received royalties from pesi (video sales of presentations); has received consulting fees from maps pbc; has received payment from pesi (speaking) and the california institute of integral studies (training workshops); has received honoraria from harvard medical school, sounds true, the integrative psychiatry institute and vital (speaking); has received support from maps pbc for attending meetings/travel; and owns stock in awakn life sciences. s.k. has received grants/contracts/consulting fees from maps pbc, pharmaceutical companies, va hospitals and university research groups for providing supervision and training to psychodiagnostic assessors on a variety of research studies. k.p. g. has received consulting fees from maps pbc for training assessors in psychodiagnostic assessment on ptsd treatment trials and from other research studies/groups conducting similar work. k.t. has received payment/honoraria from maps us (education and study activities in israel), maps pbc (senior trainer and supervisor therapist) and maps israel (co founder and ceo) and meeting/travel support from maps pbc. c.h. is a maps pbc employee; has received consulting fees from cybin (unrelated molecule and indication in the psychedelics field); and has received meeting/travel support from maps pbc. a.d.b. was previously an employee of maps pbc; has received consulting fees (to tulip medical consulting); has received meeting travel/support from maps pbc; and served as cmo (while previously an employee of maps pbc) and attended data safety monitoring board meetings without any voting rights. r.d. is the founder and president (salaried employee) of maps and is a member of the board of maps and maps pbc. b.y. k. is an employee of maps pbc, was previously an employee of maps and has received support from maps pbc and maps for attending meetings/travel. publisher’s note springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. a list of authors and their affiliations appears at the end of the paper. a list of members and their affiliations appears in the supplementary information. change history 10/7/2024 a correction to this paper has been published: 10.1038/s41591 024 03331 w jennifer m. mitchell, email: jennifer.mitchell@ucsf.edu mapp2 study collaborator group: charlotte harrison, berra yazar klosinski, wael garas, darrick may, cole marta, susan walker, elizabeth nielson, gregory wells, randall brown, revital amiaz, yair wallach, ray worthy, alia lilienstein, and amy emerson the online version contains supplementary material available at 10.1038/s41591 023 02565 4. this section collects any data citations, data availability statements, or supplementary materials included in this article. consort checklist, mapp2 study collaborators, supplementary methods, supplementary figs. 1 and 2, supplementary tables 1 9 and supplementary references. statistical source data. statistical source data. the data that support the findings of this study are available from the sponsor beginning 1 year after completion of the trial. however, restrictions apply to the availability of these data, which were used under license for the current study and so are not publicly available. data are, however, available from the authors upon reasonable request and with the permission of the sponsor. all requests for raw and analyzed data are promptly reviewed to verify if the request is subject to any confidentiality obligations. participant related data not included in the paper were generated as part of clinical trials and may be subject to participant confidentiality. any data that can be shared will be released via a data use agreement. proposals should be directed to https:/maps.org/datause. source data are provided with this paper. commercially available software (sas version 9.4 or higher, sas institute) was used for analyses, in keeping with the statistical analysis plan. articles from nature medicine are provided here courtesy of nature publishing group connect with nlm national library of medicine 8600 rockville pike bethesda, md 20894
supported by an independent group of experts expressed concerns that the data from clinical trials did not outweigh risks for treatment of post traumatic stress disorder. by andrew jacobs an independent advisory panel of the food and drug administration rejected the use of mdma assisted therapy for post traumatic stress disorder on tuesday, highlighting the unparalleled regulatory challenges of a novel therapy using the drug commonly known as ecstasy. before the vote, members of the panel raised concerns about the designs of the two studies submitted by the drug’s sponsor, lykos therapeutics. many questions focused on the fact that study participants were by and large able to correctly guess whether they had been given mdma, also known by the names of ecstasy or molly. the panel voted 9 2 on whether the mdma assisted therapy was effective, and voted 10 1 on whether the proposed treatment’s benefits outweighed its risks. other panelists expressed concerns over the drug’s potential cardiovascular effects, and possible bias among the therapists and facilitators who guided the sessions and may have positively influenced patient outcomes. a case of misconduct involving a patient and therapist in the study also weighed on some panelists’ minds. many of the committee members said they were especially worried about the failure of lykos to collect detailed data from participants on the potential for abuse of a drug that generates feelings of bliss and well being. “i absolutely agree that we need new and better treatments for ptsd,” said paul holtzheimer, deputy director for research at the national center for ptsd, a panelist who voted no on the question of whether the benefits of mdma therapy outweighed the risks.

 by will stone a dose of mdma. the drug has been studied as a treatment for ptsd and fda is now considering whether to approve it. travis dove for the washington post/getty images hide caption a panel of experts advising the food and drug administration on the use of the psychedelic mdma for post traumatic stress disorder found on tuesday that the available evidence fails to show that the drug is effective or that its benefits outweigh its risks. it represents a major setback for proponents of the drug and its sponsor lykos therapeutics, potentially jeopardizing fda approval of the treatment. following public comment and discussion, the panel voted 9 2 that mdma   in combination with talk therapy   is not effective for treating ptsd. and they voted 10 1 that the benefits of mdma treatment don’t outweigh its risks. while the fda puts stock in the panel’s advice, it does not have to follow their recommendation. however, that would be surprising given the host of concerns raised during the all day meeting. remarks during the meeting from fda staff and members of the advisory panel highlighted some major shortcomings in the clinical research. these include uncertainties and gaps in the data, unanswered questions about its potential for abuse and a lack of evidence supporting the psychological approach used in the therapy sessions. “it seems like there are so many problems with the data,” said melissa barone, one of the panelists and a psychologist with the va maryland health care system.